<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96743</article-id><article-id pub-id-type="doi">10.7554/eLife.96743</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96743.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>The co-receptor Tetraspanin12 directly captures Norrin to promote ligand-specific β-catenin signaling</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bruguera</surname><given-names>Elise S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1983-3013</contrib-id><email>ebruguer@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mahoney</surname><given-names>Jacob P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" deceased="yes"><name><surname>Weis</surname><given-names>William I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5583-6150</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="fn1"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Departments of Molecular &amp; Cellular Physiology and Structural Biology, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Araç</surname><given-names>Demet</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>University of Chicago</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University Frankfurt</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="fn" id="fn1"><label>†</label><p>Deceased</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>01</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP96743</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-27"><day>27</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-02-03"><day>03</day><month>02</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.02.03.578714"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-22"><day>22</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96743.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-13"><day>13</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96743.2"/></event></pub-history><permissions><copyright-statement>© 2024, Bruguera et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Bruguera et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96743-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96743-figures-v1.pdf"/><abstract><p>Wnt/β-catenin signaling directs animal development and tissue renewal in a tightly controlled, cell- and tissue-specific manner. In the mammalian central nervous system, the atypical ligand Norrin controls angiogenesis and maintenance of the blood-brain barrier and blood-retina barrier through the Wnt/β-catenin pathway. Like Wnt, Norrin activates signaling by binding and heterodimerizing the receptors Frizzled (Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), leading to membrane recruitment of the intracellular transducer Dishevelled (Dvl) and ultimately stabilizing the transcriptional coactivator β-catenin. Unlike Wnt, the cystine knot ligand Norrin only signals through Fzd4 and additionally requires the co-receptor Tetraspanin12 (Tspan12); however, the mechanism underlying Tspan12-mediated signal enhancement is unclear. It has been proposed that Tspan12 integrates into the Norrin-Fzd4 complex to enhance Norrin-Fzd4 affinity or otherwise allosterically modulate Fzd4 signaling. Here, we measure direct, high-affinity binding between purified Norrin and Tspan12 in a lipid environment and use AlphaFold models to interrogate this interaction interface. We find that Tspan12 and Fzd4 can simultaneously bind Norrin and that a pre-formed Tspan12/Fzd4 heterodimer, as well as cells co-expressing Tspan12 and Fzd4, more efficiently capture low concentrations of Norrin than Fzd4 alone. We also show that Tspan12 competes with both heparan sulfate proteoglycans and LRP6 for Norrin binding and that Tspan12 does not impact Fzd4-Dvl affinity in the presence or absence of Norrin. Our findings suggest that Tspan12 does not allosterically enhance Fzd4 binding to Norrin or Dvl, but instead functions to directly capture Norrin upstream of signaling.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Wnt</kwd><kwd>cell signaling</kwd><kwd>specificity</kwd><kwd>co-receptor</kwd><kwd>nanodiscs</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM131747</award-id><principal-award-recipient><name><surname>Weis</surname><given-names>William I</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>EY031947</award-id><principal-award-recipient><name><surname>Bruguera</surname><given-names>Elise S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM126642</award-id><principal-award-recipient><name><surname>Mahoney</surname><given-names>Jacob P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Biophysical binding and structural prediction studies reveal that Tetraspanin12 directly binds the ligand Norrin, in a manner that is negatively cooperative with Norrin-Fzd4 binding and competitive with Norrin-LRP5/6 binding.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Wnt/β-catenin signaling is essential to metazoan development, tissue homeostasis, and regeneration. Wnts are secreted growth factors that act through simultaneous binding to, and heterodimerization of, two membrane co-receptors: Frizzled (Fzd1-10 in humans) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) (<xref ref-type="bibr" rid="bib7">Bourhis et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Janda et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Tsutsumi et al., 2023</xref>). Fzd recruits the cytoplasmic protein Dishevelled (Dvl1/2/3 in humans) (<xref ref-type="bibr" rid="bib42">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>; <xref ref-type="bibr" rid="bib76">Tauriello et al., 2012</xref>; <xref ref-type="bibr" rid="bib92">Yang-Snyder et al., 1996</xref>), which is necessary to recruit and inhibit the proteins responsible for the constitutive degradation of β-catenin (<xref ref-type="bibr" rid="bib16">Cliffe et al., 2003</xref>; <xref ref-type="bibr" rid="bib57">Piao et al., 2008</xref>; <xref ref-type="bibr" rid="bib65">Schwarz-Romond et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Stamos et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Zeng et al., 2008</xref>). Wnt morphogens thereby stabilize β-catenin to induce signaling. β-Catenin directs the transcription of genes that drive cell division, migration, and differentiation during development as well as stem cell maintenance and renewal throughout the lifecycle (<xref ref-type="bibr" rid="bib61">Rim et al., 2022</xref>). Consequently, dysregulated β-catenin signaling can lead to cancer and degenerative diseases (<xref ref-type="bibr" rid="bib50">Nusse and Clevers, 2017</xref>).</p><p>The secreted ligand Norrin, which is structurally distinct from Wnt, binds to Fzd4 and LRP5/6 to activate β-catenin signaling (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>; <xref ref-type="bibr" rid="bib89">Xu et al., 2004</xref>). Norrin is a disulfide-linked dimer with a transforming growth factor-β-like cystine knot fold that selectively binds the Fzd4 cysteine-rich domain (CRD) with high affinity, as well as LRP5/6 β-propeller-EGF repeats 1 and 2 (E1E2) and heparan sulfate proteoglycans (HSPGs) (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>; <xref ref-type="bibr" rid="bib89">Xu et al., 2004</xref>). Norrin is specifically required for retinal vascularization and blood-retina barrier (BRB) integrity as well as blood-brain barrier (BBB) integrity in the cerebellum (<xref ref-type="bibr" rid="bib86">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib95">Ye et al., 2009</xref>), where it is partially redundant with Wnt7a/7b signaling (<xref ref-type="bibr" rid="bib87">Wang et al., 2018</xref>).</p><p>With 10 different Fzd subtypes and 19 different Wnts, along with Norrin, in the human genome, exquisite spatial and temporal signaling specificity is achieved through differential expression patterns (<xref ref-type="bibr" rid="bib49">Nusse and Varmus, 1992</xref>) and pairwise affinities (<xref ref-type="bibr" rid="bib20">Dijksterhuis et al., 2015</xref>) of the receptors and ligands. Specificity is also achieved through the expression of accessory proteins or co-receptors that modulate the expression levels, activity, or localization of core pathway components (<xref ref-type="bibr" rid="bib17">Cruciat and Niehrs, 2013</xref>; <xref ref-type="bibr" rid="bib64">Schulte, 2015</xref>). For example, the adhesion G protein-coupled receptor Gpr124 and GPI-anchored cell-surface metalloprotease inhibitor RECK were recently found to selectively enhance Wnt7a/7b signaling through a direct RECK-Wnt7a/7b interaction to control angiogenesis and maintenance of the BBB in the central nervous system (<xref ref-type="bibr" rid="bib13">Cho et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Eubelen et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Vallon et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Vanhollebeke et al., 2015</xref>). Similarly, the tetraspanin Tspan12 is required for Norrin-directed retinal angiogenesis and maintenance of the BRB (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>). Mutations in Norrin, Fzd4, LRP5, β-catenin, and Tspan12 are associated with inherited diseases of the retinal vasculature, most notably familial exudative vitreoretinopathy (FEVR) (<xref ref-type="bibr" rid="bib31">Jiao et al., 2004</xref>; <xref ref-type="bibr" rid="bib48">Nikopoulos et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Panagiotou et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Poulter et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Robitaille et al., 2002</xref>; <xref ref-type="bibr" rid="bib66">Shastry et al., 1997</xref>; <xref ref-type="bibr" rid="bib78">Toomes et al., 2004</xref>), and therapeutic targeting of Norrin/β-catenin signaling shows promise for modulating the BRB and BBB (<xref ref-type="bibr" rid="bib12">Chidiac et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Ding et al., 2023</xref>; <xref ref-type="bibr" rid="bib47">Nguyen et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">O’Brien et al., 2023</xref>; <xref ref-type="bibr" rid="bib56">Phoenix et al., 2016</xref>). However, the mechanism by which Tspan12 promotes Norrin signaling is unclear. A molecular understanding of how Tspan12 and other modulators achieve their function would enable the development of therapeutics targeting the Wnt/β-catenin pathway with greater specificity.</p><p>Members of the tetraspanin family cluster into nanodomains in the plasma membrane and modulate diverse cellular processes by binding to other membrane proteins to influence their trafficking, localization, conformation, and ligand recruitment (<xref ref-type="bibr" rid="bib44">Mattila et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Sugiyama et al., 2023</xref>; <xref ref-type="bibr" rid="bib74">Susa et al., 2024</xref>; <xref ref-type="bibr" rid="bib82">van Deventer et al., 2017</xref>). Structurally, tetraspanins have four transmembrane domains along with a small extracellular loop (SEL) and a large extracellular loop (LEL), the latter of which is implicated in many protein-protein interactions (<xref ref-type="bibr" rid="bib74">Susa et al., 2024</xref>). Tetraspanins can also recruit kinases intracellularly (<xref ref-type="bibr" rid="bib38">Lapalombella et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">Zhang et al., 2001</xref>). These observations provide potential routes by which Tspan12 might influence Norrin/β-catenin signaling. Indeed, Tspan12 has been shown to co-traffic, co-localize, and co-immunoprecipitate (co-IP) with Fzd4 and Norrin, all of which require the Tspan12 LEL (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>), and purified Tspan12 LEL, grafted onto an antibody, captured Norrin from conditioned media (<xref ref-type="bibr" rid="bib29">Hsieh and Chang, 2021</xref>). In addition, bioluminescence resonance energy transfer experiments suggest that Tspan12 forms Tspan12-Tpsan12 homodimers and Tspan12-Fzd4 heterodimers in cells (<xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>). Tspan12 restores signaling when the Norrin-Fzd4 interface is weakened by point mutations (<xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>), suggesting that Tspan12 might enhance Norrin-Fzd4 binding. However, it is unclear whether Tspan12 achieves this function through a direct interaction with either Fzd4 or Norrin. Furthermore, whether or how Tspan12 works with the core Fzd4 and LRP5/6 co-receptor pair to transduce Norrin signaling is unknown.</p><p>Here, we use purified Norrin and purified receptors reconstituted in lipid nanodiscs to explore the mechanism of Tspan12 action in Norrin/β-catenin signaling. We demonstrate that Tspan12 directly binds Norrin with high affinity and show that Norrin-Tspan12 binding is compatible with Norrin-Fzd4 binding, but not LRP6 or HSPG binding. Our work supports a model in which Tspan12-expressing cells preferentially capture Norrin, which is then handed off to Fzd4 for association with LRP5/6 and consequent signaling.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Tspan12 binds Norrin, but not Fzd4, with high affinity</title><p>We first sought to determine whether Tspan12 directly binds Norrin. We purified Tspan12, reconstituted it into lipid nanodiscs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), and found that Tspan12 directly binds purified Norrin with an affinity of 10.4±1.2 nM as measured by biolayer interferometry (BLI) (<xref ref-type="fig" rid="fig1">Figure 1A–D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). This interaction is stronger when Tspan12 is in a lipid environment than when it is in a glyco-diosgenin (GDN) detergent micelle (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Full-length Tspan12 and the purified LEL bind Norrin with similar affinity (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). A purified chimera of Tspan12 with the LEL replaced by that of Tspan11, which does not enhance Norrin signaling (<xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>), does not bind Norrin (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Together, these findings demonstrate that direct Norrin-Tspan12 binding is mediated by the Tspan12 LEL.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Tspan12 binds directly to Norrin with nanomolar affinity via the large extracellular loop (LEL).</title><p>(<bold>A</bold>) Schematic of biolayer interferometry (BLI) setup for Tspan12-Norrin binding: Tspan12 lacking the C-terminal tail (∆C), inserted into biotinylated nanodiscs, is immobilized on a streptavidin-coated biosensor, and Norrin association and dissociation are monitored in real time. (<bold>B</bold>) BLI traces of Norrin at indicated concentrations binding to and dissociating from Tspan12. (<bold>C</bold>) Steady-state binding curve fit to Norrin-Tspan12 binding (mean ± SD from three independent replicates at each concentration of Norrin) gives a K<sub>D</sub> of 10.4±1.2 nM (mean ± SEM). (<bold>D</bold>) Observed association rate constant (K<sub>obs</sub>), determined from fitting BLI association traces (mean ± SD in three independent experiments), is linearly dependent on Norrin concentration with a slope K<sub>on</sub> = 0.00019 ± 0.00003 nM <sup>–1</sup> s<sup>–1</sup> (mean ± SEM). When combined with the K<sub>off</sub> = 0.0014 ± 0.00016 s<sup>–1</sup> (mean ± SEM) determined from fitting the dissociation traces, we obtain a kinetic K<sub>D</sub> of 7.4±1.4 nM (mean ± SEM). (<bold>E</bold>) BLI traces of the soluble MBP-tagged Tspan12 LEL domain, at the indicated concentrations, associating to and dissociating from a biosensor loaded with MBP-tagged Norrin. Kinetic fitting gives an apparent affinity of 16±3 nM (mean ± SEM). (<bold>F</bold>) BLI traces of 10, 32, or 100 nM Norrin show no binding to a biosensor loaded with a nanodisc-embedded chimeric Tspan12 with the LEL replaced by that of Tspan11.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Steady-state interference shift and K<sub>obs</sub> values used to generate <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96743-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Tspan12 purification.</title><p>(<bold>A</bold>) Schematic of Tspan12 purification. Human Tspan12∆C (truncated at residue 252 after the fourth transmembrane domain) was tagged with the Rho1D4 tag TETSQVAPA and expressed in Sf9 cells by baculovirus. Detergent-solubilized Tspan12 was affinity purified on anti-Rho1D4 antibody resin followed by size exclusion chromatography. Panel A was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/q49x347">BioRender.com</ext-link>. (<bold>B</bold>) Superose 6 10/300 size exclusion traces of Tspan12 purified in DDM (teal) or exchanged into glyco-diosgenin (GDN) during the affinity chromatography step (pink); the final concentrated product in GDN showed no signs of aggregation (purple). Indicated fractions of GDN-solubilized Tspan12 (pink trace) were run on (<bold>C</bold>) SDS-PAGE; boxed fractions were pooled and concentrated. (<bold>D</bold>) Size exclusion traces of empty nanodiscs (black) or Tspan12 reconstituted into excess MSP1D1 nanodiscs (pink). Tspan12 content of fractions was quantified by dot blot (anti-Rho1D4) and dot intensity was plotted accordingly (green). (<bold>E</bold>) Peak Tspan12-containing fractions from (<bold>D</bold>) were affinity purified on anti-Rho1D4 resin. Shown is an SDS-PAGE gel of the load, flowthrough, and eluate. (<bold>F</bold>) Uranyl acetate negative stain micrograph of final nanodisc-reconstituted Tspan12. Scale bar is 20 nm.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original files of gels in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Labeled gels in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Tspan12 and Fzd4 each bind Norrin, but not one another, with high affinity through their extracellular domains.</title><p>(<bold>A</bold>) Biolayer interferometry (BLI) traces showing non-biotinylated Tspan12 nanodiscs in solution binding to biosensor-immobilized biotinylated MBP-Norrin (flipped setup compared to <xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Overlaid fits (black dashed line) give an apparent affinity of 34±11 nM. (<bold>B</bold>) BLI traces showing weak binding of indicated concentrations of Tspan12 in glyco-diosgenin (GDN) detergent to biosensor-immobilized biotinylated MBP-Norrin. (<bold>C</bold>) BLI trace showing no binding of MBP-tagged Tspan12 large extracellular loop (LEL) at 18 µM to biosensors loaded with nanodisc-embedded Fzd4. (<bold>D</bold>) BLI traces showing no binding of the soluble Fzd4 CRDL up to 32 µM to biosensors loaded with nanodisc-embedded Tspan12.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We next investigated the putative Fzd4-Tspan12 interaction, which has been shown by co-IP to depend on the Tspan12 LEL (<xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>). We did not detect binding between the purified LEL and nanodisc-embedded Fzd4 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>) nor between the Fzd4 extracellular domain (the CRD along with the linker to the transmembrane domains, termed ‘CRDL’) and nanodisc-embedded Tspan12 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). However, this does not definitively rule out a direct interaction between the two receptors, as it may be weak and require a two-dimensional (2D) membrane environment and/or be mediated, at least in part, by the transmembrane domains.</p></sec><sec id="s2-2"><title>Identification of the Norrin-Tspan12 binding site</title><p>To determine whether the Norrin-Tspan12 interaction would be spatially compatible with Norrin binding to other co-receptors, we sought structural information on the Norrin-Tspan12 binding interface. While individual crystal structures of Norrin alone and Norrin bound to both the Fzd4 CRD and the heparin mimic sucrose octasulfate (SOS) have been solved (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Shen et al., 2015</xref>), no experimental structure of Tspan12 or Norrin-bound Tspan12 exists. We used AlphaFold (<xref ref-type="bibr" rid="bib25">Evans et al., 2022</xref>; <xref ref-type="bibr" rid="bib32">Jumper et al., 2021</xref>) to predict the structure of Tspan12 alone (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>), bound to a single protomer of Norrin (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>), and bound to a Norrin dimer (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F and G</xref>). As expected, the predicted structure of Norrin within the AlphaFold models is identical to the experimentally determined structure of Norrin (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>). The Tspan12 LEL structure is nearly identical between the three predicted models, irrespective of Norrin binding (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I–K</xref>). However, the three models of Tspan12 vary slightly in the position of the SEL and LEL relative to the transmembrane domains (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>), which we attribute to uncertainty in the prediction: the SEL and the extracellular ends of all four transmembrane domains, which link the SEL and LEL to the transmembrane domains and therefore control their positioning, exhibit lower predicted local distance difference test (pLDDT) scores, indicating lower confidence in their predicted positions (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B, D, and F</xref>). This uncertainty is consistent with the variability in conformations adopted by tetraspanin transmembrane domains, which have been solved with a cavity between the TMs opening extracellularly (<xref ref-type="bibr" rid="bib40">Lipper et al., 2023</xref>; <xref ref-type="bibr" rid="bib80">Umeda et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Zimmerman et al., 2016</xref>) or with more tightly packed transmembrane domains (<xref ref-type="bibr" rid="bib23">El Mazouni and Gros, 2022</xref>; <xref ref-type="bibr" rid="bib73">Susa et al., 2021</xref>; <xref ref-type="bibr" rid="bib90">Yanagisawa et al., 2023</xref>). The transition between these states has also been observed in molecular dynamics simulations (<xref ref-type="bibr" rid="bib100">Zimmerman et al., 2016</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mutational analysis of AlphaFold-predicted Tspan12-Norrin binding site.</title><p>(<bold>A</bold>) AlphaFold model of one Norrin protomer (yellow) bound to Tspan12 (purple), with the expected location of the plasma membrane shown in gray. (<bold>B</bold>) Zoomed view of the predicted Tspan12/Norrin binding site, front and rear view (flipped 180°). Predicted polar interactions are indicated with dark gray dashed lines. Within the binding interface, Site 1 (red), Site 2 (teal), and Site 3 (blue) are indicated. Bold residue labels indicate residues mutated for binding assays. (<bold>C</bold>) AlphaFold model of Tspan12 bound to Norrin dimer and (<bold>D</bold>) zoomed view of indicated area, showing the predicted polar interaction between residue S82 on the second Norrin protomer (orange) and residue E170 on Tspan12, termed Site 4 (orange). (<bold>E</bold>) Binding affinities (mean ± SD) for the indicated Norrin mutants binding to full-length wild-type (WT) Tspan12 and (<bold>F</bold>) WT Norrin binding to the indicated Tspan12 mutants, calculated from association and dissociation fits to biolayer interferometry (BLI) traces of 32 nM Norrin binding to Tspan12 in triplicate (see <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A and B</xref>). Colors correspond to sites within the binding interface. Kinetic traces and kinetic constants are shown in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>, and affinities and kinetic constants are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Norrin-Tspan12 mutant affinities used to generate <xref ref-type="fig" rid="fig2">Figure 2E and F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96743-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>AlphaFold structural prediction of Tspan12 bound to Norrin.</title><p>(<bold>A</bold>) Cartoon of tetraspanin structure, comprised of transmembrane helices 1–4, a small extracellular loop (SEL, between helices 1 and 2) and a large extracellular loop (LEL, between helices 3 and 4). Eye icon indicates the viewing angle of AlphaFold models in the remainder of this figure (<bold>B, D, F, I–P</bold>) relative to this cartoon. (<bold>B</bold>) The structure of full-length human Tspan12 alone was predicted with AlphaFold. The best-scoring model is shown, colored by the per-residue predicted local distance difference test (pLDDT) confidence metric. (<bold>C</bold>) The predicted aligned error (PAE) for the model in B. The position of the LEL (darker purple) appears as a darker blue square in the heat map with low PAE (yellow box). The position of C-terminal residues (‘CT‘, red) is indicated; the heat map shows high PAE values for the C-terminus relative to the rest of the protein, indicating poor prediction of the relative positioning of the C-terminus. (<bold>D</bold>) The structure of full-length human Tspan12 together with one Norrin protomer (residues 25–133) was predicted with AlphaFold-Multimer and the best-scoring model is shown, colored by pLDDT. (<bold>E</bold>) The predicted aligned error for the model shown in D. The position of Norrin, Tspan12, and the LEL along the axes are indicated. Note low PAE between the LEL and parts of Norrin (yellow boxes). (<bold>F</bold>) The structure of full-length human Tspan12 together with two copies of Norrin (residues 25–133) was predicted with AlphaFold-Multimer and the best-scoring model is shown, colored by pLDDT. (<bold>G</bold>) The predicted aligned error for the model shown in F. The position of both copies of Norrin, Tspan12, and the LEL along the axes are indicated. Note low PAE between the LEL and parts of both Norrin protomers (yellow boxes). (<bold>H</bold>) Top: The structure of Norrin within the predicted structure of Tspan12+1 Norrin protomer (yellow), and within the predicted structure of Tspan12+2 Norrin protomers (orange), matches the crystal structure of Norrin (5BQ8 chains A and B; gray) with RMSDs of 0.383 and 0.413 Å respectively. Below: β strands 1, 2, 3, 4, 5, and 6 of one Norrin protomer, colored red, orange, yellow, green, blue, and purple, respectively; strands 5 and 6 are predicted to comprise the Tspan12 binding site. (<bold>I</bold>) The predicted model of Tspan12 alone (light blue) is similar to the predicted models with one (purple/yellow) or two (pink/orange) copies of Norrin, which each align with RMSDs of 1.247 and 1.057 Å, respectively, to the model of Tspan12 alone. Aligning only the LELs as shown gives RMSDs of 0.293 and 0.341 Å, respectively, and illustrates the slight variation in the predicted angle between the TMs and the LEL. The predicted position and orientation of Norrin relative to the LEL is unchanged between the one-protomer and two-protomer models. (<bold>J</bold>) Tetraspanin LELs are composed of helices A, B, C, D, and E. Helices C and D are the least conserved and are implicated in binding partner interactions (<xref ref-type="bibr" rid="bib74">Susa et al., 2024</xref>). Black double lines represent disulfide bridges. Viewing angle is indicated by the eye in A. (<bold>K</bold>) Close-up of aligned LELs from I. (<bold>L</bold>) The predicted structure of the Tspan12 LEL (from the 1 Tspan12 : 1 Norrin protomer model; residues 123–215; purple) aligns to the experimentally determined structure of CD81 LEL (5TCX residues 123–198; gray), with an RMSD of 3.997 Å. CD81 is a C4 tetraspanin; disulfide bonds for Tspan12 and CD81 are shown in pink and black, respectively. (<bold>M</bold>) The predicted Tspan12 LEL (purple) aligns to the Uroplakin 1A LEL (8JJ5, residues 125–226; gray), a C6 tetraspanin, with an RMSD of 4.215 Å. (<bold>N</bold>) The predicted Tspan12 LEL (purple) aligns to the Peripherin-2 LEL (7ZW1, residues 126–258; gray), a C6 tetraspanin, with an RMSD of 2.528 Å. (<bold>O</bold>) The predicted interaction between Norrin and Tspan12 involves helices C and D of the LEL and residues on β5 and β6 of Norrin. (<bold>P</bold>) The predicted interaction between Norrin and Tspan12 colored by surface electrostatics (APBS) shows a highly polar interaction involving a basic patch on Norrin and an acidic patch on Tspan12.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Purification of Norrin and Tspan12 mutants.</title><p>(<bold>A</bold>) Stain-free non-reducing SDS-PAGE gels of Sf9 supernatant media (‘load’), amylose resin flowthrough (‘flothru’), amylose eluate (‘elu’), and pooled fractions after size exclusion (‘SEC’) for wild-type (WT) and indicated mutant MBP-Norrin. (<bold>B</bold>) Stain-free SDS-PAGE gels of DDM-solubilized Expi293 membranes (‘sol’), supernatant post-ultracentrifugation (‘load’), 1D4 antibody resin eluate (‘elu’), and pooled fractions after size exclusion (‘SEC’) for full-length WT and indicated mutant Tspan12.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Original files of gels in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig2-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Labeled gels in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Binding kinetics of Norrin and Tspan12 mutants.</title><p>(<bold>A</bold>) Representative biolayer interferometry (BLI) association and dissociation traces of 32 nM wild-type (WT) or mutant Norrin binding to immobilized WT Tspan12, and for (<bold>B</bold>) 32 nM WT Norrin binding to immobilized WT or mutant Tspan12. Colors correspond to sites within the binding interface defined in <xref ref-type="fig" rid="fig2">Figure 2</xref>. (<bold>C and D</bold>) Rate constant K<sub>on</sub> (mean ± SD) calculated from association and dissociation fits to traces shown in A and B, respectively; each mutant was measured in triplicate. (<bold>E and F</bold>) Rate constant K<sub>off</sub> (mean ± SD) calculated from dissociation fits to traces shown in A and B, respectively; each mutant was measured in triplicate. Across the board, differences in K<sub>D</sub> for mutants compared to WT (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>) were driven largely by differences in K<sub>off</sub>. Kinetic constants reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Binding affinity and kinetics of mutant Norrin binding to mutant Tspan12.</title><p>(<bold>A</bold>) Representative biolayer interferometry (BLI) association and dissociation traces showing 32 nM mutant Norrin binding to immobilized mutant Tspan12 relative to the WT/WT binding (gray) for mutants at Site 1 (red), Site 2 (teal), Site 3 (blue), and Site 4 (orange). For each site, mutated residues on Norrin and Tspan12 are predicted to interact according to the AlphaFold structure; in the case of charge-swapped mutations (i.e., Sites 1, 3, and 4), we hypothesized that the mutations to the two proteins may be compensatory. (<bold>B</bold>) Binding affinities calculated from kinetic fits to traces in A for the indicated mutant pairs. The charge-swapped mutants at Site 1, Norrin R107E/R115E and Tspan12 E173K/D175K, do not bind appreciably at 32 nM Norrin. At Site 3, charge-swapped Norrin K102E/R121E and Tspan12 196K/S199K binding is rescued to WT/WT levels compared to the much weaker binding affinities of either mutant for its WT counterpart: i.e., the mutations are compensatory. At Site 4, the Norrin S82D mutation partially rescues the deleterious effects of Tspan12 E170K. Data represent mean ± SD from three replicates. Binding affinities and kinetic constants reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>C</bold>) K<sub>on</sub> and (<bold>D</bold>) K<sub>off</sub>, calculated from each individual trace shown in A, measured in triplicate. Plots represent three replicates ± SD, and kinetic constants are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. WT, wild-type.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig2-figsupp4-v1.tif"/></fig></fig-group><p>We were most interested in the predicted structure of the Norrin-binding domain of Tspan12, the LEL. Tetraspanin LELs contain five helices, A–E (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1J</xref>), and are stabilized by 2, 3, or 4 disulfide bonds (<xref ref-type="bibr" rid="bib74">Susa et al., 2024</xref>). The predicted Tspan12 LEL ‘stalk’ helices A and B resemble helices A and B within experimental structures of other LEL domains, such as CD81 (<xref ref-type="bibr" rid="bib100">Zimmerman et al., 2016</xref>), Uroplakin 1A (<xref ref-type="bibr" rid="bib90">Yanagisawa et al., 2023</xref>), and Peripherin 2 (<xref ref-type="bibr" rid="bib23">El Mazouni and Gros, 2022</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1L–N</xref>). The hypervariable ‘head’ region comprised of helices C and D align less well to other tetraspanins, as does helix E, where residue positions were predicted with lower pLDDT confidence scores.</p><p>The AlphaFold model predicts a highly acidic patch on the C and D helices of the Tspan12 LEL as the binding site for a highly basic patch on Norrin β strands 5 and 6 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H–K and O–P</xref>), burying about 1200 Å<sup>2</sup> of surface area. Salt bridges are predicted between Norrin residues R107 and R115 and Tspan12 residues E175 and D173, respectively; we have termed this region Site 1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The model also predicts a region composed of hydrophobic contacts including Norrin residues T119 and T117 and Tspan12 residues T166, L169, and L198, which we have termed Site 2. Site 3 consists of electrostatic interactions between Norrin residues K102 and R121 and Tspan12 residues E196 and S199, as well as the C-terminal end of the Tspan12 helix D dipole. If two Norrin protomers are included in the Norrin-Tspan12 AlphaFold Multimer prediction (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), an additional contact is predicted between E170 on Tspan12 and S82 on the second copy of Norrin, termed Site 4 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>To experimentally test this structural prediction, charge-reversal mutations were introduced at side chains involved in polar interactions within Sites 1, 3, and 4; at Site 2, smaller buried side chains were mutated to bulkier residues (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). The binding of purified mutants was quantified using BLI by fitting the association and dissociation traces of Norrin at a single concentration (32 nM) to obtain kinetic binding constants (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). By this metric, wild-type (WT) Norrin binds full-length WT Tspan12 with an apparent affinity of 2.5±0.2 nM (mean ± SEM). Relative to this benchmark, mutations within Site 1 diminished Norrin-Tspan12 binding: the Norrin double mutant R107E/R115E binds WT Tspan12 with 84-fold weaker affinity, and WT Norrin binds Tspan12 E173K/D175K with 3.4-fold weaker affinity (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, red bars). Given that these charge-swapping mutations were made at sites predicted to interact, we tested the binding of mutant Norrin R107E/R115E to mutant Tspan12 E173K/D175K, with the hypothesis that these mutations might be compensatory. However, the two mutants did not bind one another at the concentration of Norrin tested (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>).</p><p>Mutations to hydrophobic contacts at Site 2 have more modest effects on Tspan12-Norrin affinity. The conservative mutation L198Y in Tspan12 does not appreciably change its binding affinity for Norrin, while the double mutation T117Y/T119Y in Norrin decreases its affinity for WT Tspan12 12-fold (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, green bars). A T119P mutation in Norrin is associated with Norrie disease in humans, but this mutation may destabilize Norrin structure in addition to disrupting the Norrin-Tspan12 binding interface.</p><p>The most dramatic effects on Tspan12-Norrin binding were observed when mutations were made at Site 3. The mutations K102E/R121E together decrease Norrin’s affinity for WT Tspan12 by two orders of magnitude, and WT Norrin binds Tspan12 E196K/S199K with sixfold weaker affinity than WT Tspan12 (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, blue bars). However, these two mutants (Norrin K102E/R121E and Tspan12 E196K/S199K) bind each other with an affinity of 1.3±0.06 nM (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>), slightly stronger than the WT-WT interaction. The fact that these charge-reversal mutations can compensate for one another supports the structural prediction that these two regions of Norrin and Tspan12 physically interact. Of note, a disease-associated Norrin mutation at this site, R121W, impairs signaling in a cell-based assay (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>), which we propose may be attributed to deficient Tspan12 binding.</p><p>At Site 4, Norrin S82D binds WT Tspan12 with twofold lower affinity than WT, and WT Norrin binds Tspan12 E170K with sixfold lower affinity than WT (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, orange bars). The two charge-swapped mutants Norrin S82D and Tspan12 E170K bind with an affinity of 5.2±0.7 nM (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>); thus, the mutation in Norrin at this site compensates for the deleterious effects of the mutation in Tspan12 at this site. Again, this suggests that these two residues are in proximity in the Norrin-Tspan12 complex, as in the AlphaFold-predicted model.</p><p>AlphaFold predictions vary in their accuracy even when reported with high confidence scores, with errors ranging from local backbone and side chain distortions to shifts in the orientation of entire domains (<xref ref-type="bibr" rid="bib77">Terwilliger et al., 2024</xref>). Our ability to weaken Tspan12-Norrin affinity with mutations at the predicted interface suggests that the predicted interface is correct but does not rule out the possibility that the relative orientations of Tspan12 and Norrin within the model are erroneous. At Sites 3 and 4, charge-reversal mutations on Norrin can compensate for charge-reversal mutations on Tspan12 (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), in strong support of direct interactions between the predicted mutated sites. However, this was not the case for Site 1. Nevertheless, this structural model allowed us to generate testable hypotheses regarding whether Norrin could bind Tspan12 alongside its other binding partners, which we next sought to test experimentally.</p></sec><sec id="s2-3"><title>Norrin can bind Tspan12 simultaneously with Fzd4, but not HSPGs</title><p>When the predicted Norrin-Tspan12 structure is compared with the available crystal structure of Norrin bound to the Fzd4 CRD and the heparin mimic SOS (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>), it is evident that the binding sites for Tspan12 and SOS on Norrin overlap (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Indeed, the Norrin-Tspan12 interaction is inhibited by increasing concentrations of SOS with a K<sub>i</sub> of 34±4 µM (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Of note, both residues mutated in the Site 1 Norrin mutant R107E/R115E, which impair Tspan12 binding (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), are also part of the SOS binding site (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>). The deleterious effect of the Norrin mutation R115L seen in FEVR patients has previously been attributed to deficient HSPG binding; our data suggest that this mutation may also impair Tspan12 binding.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Norrin-Tspan12 binding is competitive with heparan sulfate proteoglycans but compatible with Fzd4 binding.</title><p>(<bold>A</bold>) The AlphaFold-predicted structure of Tspan12 (purple) bound to a Norrin dimer (yellow/orange), aligned to the crystal structure (5BQC) of a Norrin dimer bound to the Fzd4 CRD (blue) and sucrose octasulfate (SOS) (red). A zoomed view of the indicated region shows an overlap in the predicted binding site of Tspan12 with that of SOS, suggesting that Tspan12 and SOS cannot bind simultaneously to Norrin. (<bold>B</bold>) Displacement of Norrin (32 nM) from immobilized Tspan12 by increasing concentrations of SOS, as measured by biolayer interferometry (BLI) (see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). The equilibrium binding signal is plotted as a percent of signal in the absence of SOS (mean ± SD of three independent experiments), yielding a K<sub>i</sub> of 34±4 µM. (<bold>C</bold>) Side view of structures in A. A zoomed view of the indicated region shows that Tspan12 is predicted to occupy a site on Norrin adjacent to, but not overlapping with, the Fzd4 binding site; adjacent residues are shown. Norrin from the Tspan12-bound AlphaFold model (yellow) and the Fzd4 CRD-bound crystal structure (5BQC, gray) are overlaid. (<bold>D</bold>) Fzd4 CRDL does not fully compete with Tspan12-Norrin binding, as shown by equilibrium binding of 32 nM Norrin to Tspan12 immobilized on paramagnetic particles in the presence of increasing concentrations of purified Fzd4 CRDL. Bound Norrin and Norrin in the supernatant were both quantified by western blot (anti-Rho1D4; see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) and used to calculate bound Norrin as a percentage of total Norrin. The expected competition curve, assuming fully competitive binding sites, was simulated (gray dashed line) given starting concentrations of 50 nM Tspan12 and 32 nM Norrin, and binding affinities of 10.4 nM for Tspan12-Norrin and 200 nM for Fzd4 CRDL-Norrin. However, the data better fit a model in which CRDL binding to Norrin shifts Norrin affinity for Tspan12 (blue line). Data represent mean ± SD of three replicates. (<bold>E</bold>) BLI traces of a ternary Fzd4-Norrin-Tspan12 large extracellular loop (LEL) complex. Biosensors loaded with nanodisc-embedded Fzd4 were first saturated with 100 nM Norrin, then bound to 32, 100, or 320 nM Tspan12 LEL. (<bold>F</bold>) BLI traces of ternary complex formation. Biosensors loaded with maltose binding protein (MBP)-tagged Norrin were pre-incubated in buffer or saturated with Fzd4 CRDL (5 µM), then bound to 100 nM MBP-tagged Tspan12 LEL (±5 µM CRDL). Tspan12 LEL did bind to Norrin in the presence of the Fzd4 CRDL (dark purple; apparent K<sub>D</sub> = 27 ± 2.8 nM), albeit more weakly than it bound to Norrin alone (light purple; apparent K<sub>D</sub> = 16 ± 1.8 nM; see also <xref ref-type="fig" rid="fig1">Figure 1E</xref>). Binding affinities were obtained from kinetic fits (black dotted line) to association and dissociation traces of MBP-LEL (100 nM) from three independent experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Interference shift and band quantification values used to generate <xref ref-type="fig" rid="fig3">Figure 3B and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96743-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Tspan12 Norrin binding can be competed with sucrose octasulfate (SOS) but not the Fzd4 CRDL domain.</title><p>(<bold>A</bold>) Representative biolayer interferometry (BLI) traces of 32 nM Norrin binding to biosensor-immobilized Tspan12 in the presence of increasing concentrations of SOS. (<bold>B</bold>) Representative western blot of Norrin in the supernatant (<bold>S</bold>) or remaining bound (<bold>B</bold>) to Tspan12 or empty nanodiscs immobilized on paramagnetic particles in the presence of 0, 0.1, 0.4, 1.6, 6, 25, or 100 µM of purified Fzd4 CRD-linker domain, with both Norrin and Tspan12 detected by anti-Rho1D4 antibody. Norrin is detected within the dynamic range, as shown by concentration standards loaded at left. Tspan12 forms SDS-induced dimers, which can be detected at about 50 kDa. (<bold>C</bold>) BLI traces showing binding of the Fzd4 CRDL to biosensor-immobilized MBP-Norrin, which reaches saturation at 3.2 µM CRDL. Equilibrium binding values obtained from the overlaid fits (black dashed lines) give a steady-state affinity of 122±38 nM (mean ± SEM), in agreement with previously reported affinity measurements (<xref ref-type="bibr" rid="bib4">Bang et al., 2018</xref>).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Original files of western blots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Labeled western blots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig3-figsupp1-v1.tif"/></fig></fig-group><p>In the same structural model, the Tspan12 binding site on Norrin is adjacent to the binding site for the Fzd4 CRD on the same protomer (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). While simultaneous binding of Tspan12 and Fzd4 to one Norrin protomer appears to be sterically compatible in this model, the adjacent regions of Tspan12 and Fzd4 are acidic and may compete for the same residues K102 and/or K104 on Norrin. In line with this prediction, Norrin-Tspan12 binding is negatively modulated by the Fzd4 extracellular domain: in a competition binding experiment, the amount of Norrin bound to nanodisc-embedded Tspan12 decreases slightly in response to increasing concentrations of Fzd4 CRDL, reaching a new non-zero plateau (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). This suggests that although the presence of Fzd4 may effectively weaken Norrin-Tspan12 affinity, Tspan12 and Fzd4 can simultaneously bind a single Norrin protomer. To test this directly, sequential binding of components was monitored by BLI. Biosensors loaded with nanodisc-embedded Fzd4 were bound to Norrin, followed by Tspan12 LEL, which bound in a concentration-dependent manner (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). However, as Norrin is a disulfide-linked dimer, this experiment was unable to show whether Fzd4 and Tspan12 were binding to the same protomer of Norrin, because the Norrin dimer may bridge this interaction. We next immobilized Norrin on the biosensors, and bound Fzd4 CRDL at a concentration expected to saturate both sites on the Norrin dimer (5 µM; see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), followed by the Tspan12 LEL (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). The Tspan12 LEL-bound CRDL-saturated Norrin with a twofold weaker apparent affinity than Norrin alone. This is again consistent with a model in which Tspan12 and Fzd4 can simultaneously bind each protomer of Norrin to form a 2:2:2 complex, but with negative cooperativity.</p></sec><sec id="s2-4"><title>Tspan12 provides additional binding sites to enhance Norrin capture</title><p>In the experiments above, the receptor elements were given a degree of freedom that they do not normally possess when the full-length receptors are embedded in the plasma membrane, and any potential allosteric effects mediated by the transmembrane domain of Tspan12 could not be assessed. Fzd4 and Tspan12 appear to co-localize even in the absence of Norrin (<xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>), thus the two receptors may together form a single, composite binding site with altered Norrin binding affinity compared to Fzd4 alone. We therefore investigated whether interactions within a membrane-embedded receptor heterodimer could impact Norrin binding. We were unable to co-purify Fzd4 and Tspan12 when the two proteins were co-expressed in cells, and separately- purified proteins could not be co-reconstituted into nanodiscs with appreciable efficiency. Therefore, we enforced a 1:1 Tspan12:Fzd4 dimer by co-expressing receptor constructs that were C-terminally tagged with complementary fragments of split GFP, which assembles to stably tether the receptors throughout expression, purification, and insertion into nanodiscs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>). We assessed the stoichiometry of the heterodimer preparations by quantitative western blotting (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), confirming that these preparations contain 1.17±0.11 Tspan12 and 1.11±0.12 Fzd4 receptors per nanodisc (i.e., per two copies of MSP belt protein), compared to 1.17±0.05 Tspan12 receptors per nanodisc in the absence of Fzd4. We have shown previously that our preparations of Fzd4 are also predominantly monomeric in nanodiscs (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>).</p><p>Norrin binds to the Tspan12/Fzd4 dimer with a K<sub>D</sub> of 2.18±0.10 nM, which is slightly tighter than Norrin’s affinity for Fzd4 alone (3.29±0.17 nM), and tighter than Norrin’s affinity for Tspan12 alone (10.4±1.2 nM) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–C</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Interestingly, Fzd4 and Tspan12/Fzd4 differ most in their ability to bind Norrin at lower concentrations (≤1 nM), yielding Hill slopes that differ significantly and reproducibly for the different receptor assemblies (1.7±0.1 for the Tspan12/Fzd4 dimer vs. 2.8±0.6 for Fzd4 alone, and 1.0±0.1 for Tspan12 alone).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Tspan12 enhances Norrin-Fzd4 binding, cell-surface binding, and Norrin-stimulated β-catenin signaling at low Norrin concentrations.</title><p>(<bold>A</bold>) Steady-state binding curves of monomeric Tspan12∆C, monomeric Fzd4, or heterodimeric Tspan12∆C/Fzd4∆C receptors in biotinylated nanodiscs binding to dimeric or (<bold>B</bold>) monomeric (C93A/C95A/C131A) Norrin by biolayer interferometry (BLI). Steady-state binding signal is plotted as a percent of B<sub>max</sub> for three independent replicates (mean ± SD). Affinities and kinetic constants are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>C</bold>) Indicated concentrations of Norrin-1D4 dimer binding to Expi293 cells transfected with Fzd4, Tspan12, or both Fzd4 and Tspan12, detected with fluorescently labeled Rho1D4 antibody and quantified by flow cytometry. Mean ± SD of three independent experiments are plotted. Co-transfection of Tspan12 increased Norrin recruitment to Fzd4-transfected cells at 0.1, 0.32, 1, and 3.2 nM Norrin (two-tailed t-test p-values of 0.00026, 0.00079, 0.0049, and 0.0018, respectively). (<bold>D</bold>) β-Catenin pathway activation resulting from increasing concentrations of Norrin was assessed in Fzd1/2/4/5/7/8-knockout HEK293T cells transfected with Tspan12 siRNA or increasing amounts of Tspan12 plasmid, along with Fzd4 and TopFlash luciferase reporter plasmids. Data are plotted as mean ± SD from triplicate wells are representative of three independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Interference shift, cell fluorescence, and luciferase activity values used to generate <xref ref-type="fig" rid="fig4">Figure 4A–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96743-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Purification of Fzd4/Tspan12 dimer and insertion into nanodiscs.</title><p>(<bold>A</bold>) Construct design of Tspan12 and Fzd4 C-terminally tagged with split GFP fragments s11 and s1–10, respectively, both downstream of a 3C protease recognition sequence. Fzd4 is additionally tagged with an N-terminal FLAG tag and Tspan12 is additionally tagged with a C-terminal 6xHis tag. The Fzd4 C-terminal PDZ ligand (ETVV) is appended after split GFP to improve expression and surface localization (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>). (<bold>B</bold>) Schematic of Tspan12/Fzd4 heterodimer expression and purification. The constructs in A were co-expressed in Sf9 cells, solubilized in <italic>n</italic>-dodecyl-β-D-maltopyranoside (DDM), and co-purified on M1 anti-FLAG affinity resin followed by size exclusion chromatography. The dimer was reconstituted into nanodiscs and further purified by size exclusion followed by capture on anti-GFP nanobody resin, from which it was eluted by 3C protease. (<bold>C</bold>) Size exclusion traces of empty nanodiscs or Tspan12/Fzd4 dimer reconstituted into excess nanodiscs, with absorbance detected at 280 and 475 nm (GFP absorption peak), on a Superose 6 Increase column. Indicated fractions were pooled for (<bold>D</bold>) SDS-PAGE, imaged using StainFree imaging (above) or GFP fluorescence (below); intact GFP is SDS-resistant. Fractions on the right side of the peak (boxed) were pooled in order to exclude any potential separately-reconstituted dimers (i.e., two nanodiscs with one receptor each, linked together by the GFP moiety). (<bold>E</bold>) Pooled fractions were purified by GFP nanobody resin and eluted with 3C protease. The load, flowthrough, and eluate are shown.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original files of gels in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Labeled gels in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Stoichiometry of receptors in nanodiscs was determined by quantitative western blot.</title><p>(<bold>A</bold>) Receptors per nanodisc in monomeric Tspan12 (mean ± SEM 1.17±0.05 Tspan12 per two MSP1D1) and heterodimeric Tspan12/Fzd4 nanodiscs (1.17±0.11 Tspan12 and 1.11±0.12 Fzd4 per two MSP1D1) as calculated from three independent samples each, with each component measured three times each by quantitative western blot. (<bold>B</bold>) Representative anti-Rho1D4 (top) and anti-His (bottom) western blots to quantify Tspan12-1D4 and His-MSP1D1, respectively, in monomeric Tspan12 reconstitutions. A known dilution series of purified protein was loaded in left lanes to generate a standard curve in the linear range of detection, against which dilutions of three nanodisc reconstitutions, loaded in duplicate in right lanes, were compared. (<bold>C</bold>) Representative anti-FLAG (top), anti-His (middle), and Neutravidin-800 (bottom) western blots to quantify FLAG-Fzd4, Tspan12-His, and biotinylated MSP1D1, respectively, in Tspan12/Fzd4 heterodimer preparations.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Original files of western blots in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Labeled western blots in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Tspan12 enhances Norrin recruitment.</title><p>(<bold>A</bold>) Representative biolayer interferometry (BLI) association and dissociation traces of dimeric Norrin binding to Fzd4 monomer or (<bold>B</bold>) Tspan12/Fzd4 heterodimer in nanodiscs. (<bold>C</bold>) Observed association rate constant K<sub>obs</sub> of Norrin dimer binding to Tspan12, Fzd4, or Tspan12/Fzd4 heterodimer in nanodiscs, plotted against Norrin concentration. Linear fits were used to obtain association rate constants reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Data represent mean ± SD for three independent replicates. (<bold>D</bold>) Representative BLI association and dissociation traces of monomeric Norrin (C93A/ C95A/C131A) binding to Fzd4 monomer or (<bold>E</bold>) Tspan12/Fzd4 heterodimer in nanodiscs. (<bold>F</bold>) Observed association rate constant K<sub>obs</sub> (mean ± SD) of Norrin monomer binding to Tspan12, Fzd4, or Tspan12/Fzd4 heterodimer in nanodiscs, plotted against Norrin monomer concentration. (<bold>G</bold>) Fzd4 surface expression on Expi293 cells transfected with empty vector, FLAG-Fzd4, or FLAG-Fzd4+Tspan12, which were then stained with M1 anti-FLAG antibody conjugated to Alexa Fluor 647. Cell fluorescence is measured by flow cytometry and plotted along with the median and interquartile range. Co-expression of Tspan12 modestly but significantly decreases surface expression of Fzd4 (Mann-Whitney test, p-value&lt;0.0001 in each of three independent experiments).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Purification and validation of monomeric Norrin.</title><p>(<bold>A</bold>) Analytical size exclusion traces of wild-type (WT) (dimeric) MBP-Norrin (yellow) and MBP-Norrin rendered monomeric (brown) via mutations C93A/C95A/C131A to eliminate the intermolecular disulfides. Purified protein was injected at 25 µM on a Superdex 200 Increase 10/300 column, resulting on an on-column concentration in excess of 2.5 µM assuming a 10-fold on-column dilution factor. (<bold>B</bold>) Non-reducing SDS-PAGE gel of WT and C93A/C95A/C131A MBP-Norrin. (<bold>C</bold>) Uranyl acetate negative stain micrograph of WT MBP-Norrin, prepared at 100 nM. Scale bar is 50 nm. Representative picked particles indicated in yellow. (<bold>D</bold>) Uranyl acetate negative stain micrograph of MBP-Norrin C93A/C95A/C131A, prepared at 100 nM. Scale bar is 50 nm. Representative picked particles indicated with circles. Yellow-circled particle appears to be large enough to potentially be a dimer; brown circles show some smaller species, which dominate. (<bold>E</bold>) 2D class averages of picked particles from C show two lobes, consistent with two copies of MBP-Norrin (54 kDa each). (<bold>F</bold>) 2D class averages of picked particles from D show small, single particles that are hard to align; they are about half the size of particles in E, consistent with one copy of MBP-Norrin. This suggests that MBP-Norrin C93A/C95A/C131A is monomeric at 100 nM. (<bold>G</bold>) β-Catenin transcriptional activity in response to 0.01–10 nM purified WT (dimeric) or 0.02–20 nM C93A/C95A/C131A (monomeric) Norrin, in Fzd1/2/4/5/7/8-knockout HEK293T cells transfected with Fzd4 and TopFlash luciferase reporter plasmids. Data are plotted as mean ± SD from n=3 replicate wells.</p><p><supplementary-material id="fig4s4sdata1"><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Original file of gel in <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s4sdata2"><label>Figure 4—figure supplement 4—source data 2.</label><caption><title>Labeled gel in <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig4-figsupp4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig4-figsupp4-v1.tif"/></fig></fig-group><p>Given this slight increase in affinity, we wondered whether Tspan12 and Fzd together can form a composite, higher affinity binding site for each Norrin protomer, or whether the heterodimer simply displayed increased avidity and was able to simultaneously bind two disulfide-linked Norrin protomers. To investigate this, we purified a monomeric mutant of Norrin, C93A/C95A/C131A, which lacks the three cysteines that link the dimer together (<xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>). This mutant elutes slightly later than WT Norrin on size exclusion chromatography, runs as a monomer on non-reducing SDS-PAGE, and produces particles of a size consistent with a monomer by negative stain electron microscopy at 100 nM (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). If heterodimeric Tspan12 and Fzd4 together form an extended, composite binding site for a single Norrin protomer, then we would expect its affinity for monomeric Norrin to be greater than that of Fzd4 alone. Purified monomeric Norrin binds Fzd4 and the Tspan12/Fzd4 heterodimer with similar affinities (13.2±1.2 nM [Hill slope = 2.0 ± 0.3] for Fzd4, vs. 11.5±1.5 nM [Hill slope = 1.0 ± 0.1] for Tspan12/Fzd4) (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D–F</xref>). This suggests that Tspan12 and Fzd4 do not cooperate to form a single, higher affinity binding site for each Norrin protomer. Monomeric Norrin bound Tspan12 alone much more weakly and did not reach saturation at 1 µM (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This behavior is consistent with the structural prediction that the binding site for Tspan12 on Norrin spans across part of the dimer interface (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). However, it is also possible that Norrin dimerization is required for the structural stability of the β strands that form the Tspan12 binding site.</p><p>If Tspan12 does not directly increase the affinity of Fzd4 for Norrin, we next hypothesized that it could be helping cells capture Norrin upstream of signaling. We transfected Expi293 cells with Fzd4, Tspan12, or both receptors together, incubated them with purified Norrin, and quantified cell-surface Norrin binding by flow cytometry (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Fzd4-transfected cells capture more Norrin when Tspan12 is co-transfected, even though Tspan12 co-expression slightly decreases Fzd4 surface expression (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3G</xref>). This is true at all concentrations of Norrin tested, although the effect is greatest at low concentrations of Norrin (≤1 nM), mirroring the results of binding assays with purified protein.</p><p>If the role of Tspan12 is to help cells capture Norrin, and if its impact on Norrin capture is most evident at low concentrations of Norrin, we would expect it to have the largest effect on β-catenin signaling at low concentrations of Norrin – i.e., Norrin should more potently stimulate β-catenin signaling in cells expressing Tspan12. To assess signaling, we transfected Fzd1/2/4/5/7/8-knockout HEK293T cells with Tspan12 siRNA or increasing amounts of Tspan12 plasmid alongside fixed amounts of Fzd4 and a β-catenin-responsive reporter plasmid (TopFlash). We then measured luciferase activity in response to increasing amounts of recombinant Norrin (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Norrin stimulation results in a bell-shaped dose-response curve, consistent with its role in heterodimerizing Fzd4 and LRP5/6 (i.e., excessive Norrin concentrations will fully saturate receptor binding sites, inhibiting receptor dimerization). In all conditions, Norrin exhibited maximal activity at or below 1 nM, the same concentration regime in which we see the largest effect of Tspan12 on Norrin binding to Fzd4-containing nanodiscs (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and Fzd4-expressing cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Contrary to our expectation, in the cell-based signaling assay, Tspan12 does not appear to have a marked effect on Norrin potency, and instead increases the amplitude of response to Norrin at all concentrations of Norrin tested.</p></sec><sec id="s2-5"><title>Tspan12 does not directly enhance formation of the Norrin/Fzd4/LRP/Dvl signaling complex</title><p>Because β-catenin signaling depends on the ability of ligands to bring together Fzd and LRP5/6, we next hypothesized that Tspan12 might increase Norrin efficacy by forming a complex with Norrin, Fzd4, and LRP5/6 to exert a direct effect on downstream signaling (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Tspan12 has been shown to co-localize and co-internalize with Fzd4, LRP5, and Norrin in Norrin-stimulated cells (<xref ref-type="bibr" rid="bib98">Zhang et al., 2017</xref>). As part of this complex, Tspan12 might modulate the direct Fzd4-Dvl interaction on the intracellular side of the membrane, since tetraspanins have been known to recruit intracellular partners (<xref ref-type="bibr" rid="bib38">Lapalombella et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">Zhang et al., 2001</xref>). This hypothesis mirrors a proposed role of Gpr124 in zebrafish, which co-IPs with Dvl (<xref ref-type="bibr" rid="bib24">Eubelen et al., 2018</xref>). An increase in Fzd4 affinity for the Dvl2 DEP domain in the presence of Tspan12, either with or without Norrin, would explain the Tspan12-mediated enhancement of signaling. To test this directly, we inserted Fzd4 alone or Tspan12/Fzd4 heterodimers into nanodiscs containing 5% PI(4,5)P<sub>2</sub>, which enhances DEP recruitment (<xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>), and measured DEP binding by BLI (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Contrary to our hypothesis, we found that the affinity of the Dvl2 DEP domain for the Tspan12/Fzd4 heterodimer is not significantly different than its affinity for Fzd4 alone (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and is unchanged in the presence of Norrin (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This is consistent with our previous findings that neither Wnt ligands nor LRP6 allosterically modulate Fzd-DEP binding (<xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Tspan12 does not directly enhance formation of a Norrin-LRP5/6-Fzd4-Dvl signaling complex.</title><p>(<bold>A</bold>) Hypothesis: Tspan12 could enhance Norrin signaling by enhancing interactions within the Norrin-LRP5/6-Fzd4-Dvl complex, including Fzd-Dvl binding and Norrin-LRP binding. (<bold>B</bold>) Representative biolayer interferometry (BLI) traces of the Dvl2 DEP domain associating to and dissociating from Fzd4 in nanodiscs containing 75:20:5 POPC:Ccholesterol:PIP<sub>2</sub>. (<bold>C</bold>) Equilibrium binding of the Dvl2 DEP domain to Fzd4 monomer or Tspan12/Fzd4 heterodimer in nanodiscs; affinities ± SEM are 183±24 and 279±46 nM, respectively. (<bold>D</bold>) Equilibrium binding of the Dvl2 DEP domain to Fzd4 monomer or Tspan12/Fzd4 heterodimer nanodiscs, each pre-saturated with 10 nM Norrin. Binding affinities are 161±21 and 274±39 nM (mean ± SEM), respectively, determined from three independent replicates. Affinities and kinetic constants are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>E</bold>) The LRP6 E1E2 domain fully competes with Tspan12-Norrin binding, as shown by decreased equilibrium binding of 32 nM Norrin to Tspan12 immobilized on paramagnetic particles in the presence of increasing concentrations of purified LRP6 E1E2 domain. Norrin was quantified by western blot (anti-Rho1D4; see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) and plotted as a percent of bound Norrin in the absence of LRP6 E1E2. The curve was fit to a competitive binding model using known binding affinities of 10.4 nM for Tspan12-Norrin and starting concentrations of 50 nM Tspan12 and 32 nM Norrin; the best fit reported a Norrin-LRP6 E1E2 binding affinity of 1.06 µM (95% CI 0.747–1.51 µM). Data represent mean ± SD of three replicates. (<bold>F</bold>) β-Catenin transcriptional activity in response to no ligand, 1 nM recombinant Norrin, or Wnt3a conditioned media (Wnt3a CM) in Fzd1/2/4/5/7/8-knockout HEK293T cells transfected with Tspan12 siRNA or indicated amount of Tspan12_pTT5 plasmid, along with Fzd4 and TopFlash luciferase reporter plasmids. Data are plotted as mean ± SD from n=3 replicate wells.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Interference shift, band quantification, and luciferase activity values used to generate <xref ref-type="fig" rid="fig5">Figure 5C–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96743-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Tspan12 and LRP6 E1E2 compete for Norrin binding.</title><p>(<bold>A</bold>) Representative western blot of Norrin bound to Tspan12 or empty nanodiscs immobilized on paramagnetic particles in the presence of 0, 0.1, 0.4, 1.6, 6, 25, or 100 µM of purified LRP6 E1E2 domain, with both Norrin and Tspan12 detected by anti-Rho1D4 antibody. Norrin is detected within the dynamic range, as shown by concentration standards loaded to the left of the ladder. (<bold>B</bold>) Association and dissociation biolayer interferometry traces of purified LRP6 (residues 20–1439, including the transmembrane domain but with a truncated C-terminus, in <italic>n</italic>-dodecyl-β-D-maltopyranoside [DDM] detergent, at 32, 100, or 320 nM) binding to MBP-Norrin-loaded biosensors. (<bold>C</bold>) Biolayer interferometry traces of 30 nM LRP6 associating to and dissociating from MBP-Norrin-loaded biosensors, pre-equilibrated with increasing concentrations of MBP-fused Tspan12 large extracellular loop (LEL).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original file of western blot in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Labeled western blot in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96743-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Finally, we wondered whether Tspan12 might cooperatively enhance Norrin-LRP5/6 binding to increase Norrin signaling efficiency. Of note, while LRP6 is known to use the β-propeller-EGF repeats 1 and 2 (E1E2) within its extracellular domain to bind Norrin (<xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>), no structural information on Norrin-LRP5/6 binding is available, and AlphaFold was unable to predict the structure of a Norrin-LRP5/6 complex with high confidence (data not shown). It has been proposed that Norrin uses a positively charged patch composed of residues K54, R90, R97, G112, and R121 to bind LRP6 <xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; of these residues, R121 forms part of the AlphaFold-predicted binding site for Tspan12 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which predicts that Tspan12 and LRP5/6 may compete for the same binding site on Norrin. Indeed, we found that Norrin can be completely displaced from nanodisc-embedded Tspan12 by increasing amounts of purified LRP6 E1E2 domain (<xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). We calculated the K<sub>i</sub> to be 1.06 µM, which agrees with previous LRP6-Norrin affinity measurements (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>). In keeping with this result, the Tspan12 LEL displayed concentration-dependent inhibition of Norrin binding to a larger portion of LRP6 (including the full extracellular and transmembrane domains but lacking a portion of the C-terminus) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>). While LRP5, but not LRP6, has been genetically implicated in Norrin-directed retinal vascularization, we expect the binding site for Norrin to be conserved in both LRP5 and LRP6 because LRP6 binds Norrin, transduces Norrin-stimulated and Tspan12-enhanced TOPFLASH signaling, and is highly homologous to LRP5 (<xref ref-type="bibr" rid="bib11">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>; <xref ref-type="bibr" rid="bib99">Zhou and Nathans, 2014</xref>).</p><p>These experiments imply that LRP5/6 and Tspan12 compete for the same binding site on Norrin or that their simultaneous binding is otherwise sterically incompatible. Furthermore, it suggests that Tspan12 does not incorporate into the Norrin-Fzd4-LRP5/6 signaling complex via interactions with Norrin. If Tspan12 competes with LRP5/6 for Norrin binding, it should inhibit signaling, which we found to be the case in cells. In TopFlash signaling assays, we observed a bell-shaped curve in response to transfected Tspan12, where high levels of Tspan12 completely inhibit Norrin-stimulated signaling (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Wnt3a signaling was moderately inhibited at the highest level of transfected Tspan12, an effect that may be due to a negative influence of Tspan12 transfection on cell-surface expression of Fzd4 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3G</xref>). However, Norrin signaling was inhibited to a greater extent and at lower levels of transfected Tspan12, which is consistent with a model in which Tspan12 competes with LRP6 for Norrin binding.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The spatiotemporal specificity of Wnt- and Norrin/β-catenin signaling is tightly controlled by a growing number of known modulators. In this study, we used biochemical approaches to investigate the molecular mechanism by which the Norrin-specific co-receptor Tspan12 enhances Norrin/β-catenin signaling. We have demonstrated direct, high-affinity binding of Norrin to Tspan12, and our mutagenesis studies corroborate a binding site on the Tspan12 LEL predicted by AlphaFold Multimer. Several mutations in the predicted interface have been associated with Norrie disease, FEVR, and other diseases of the retinal vasculature. The missense mutations of clinical significance in the Tspan12 LEL are severe enough that they would be expected to disrupt the LEL fold or lead to Tspan12 aggregation (e.g. mutations to/from cysteine or proline). The Norrie disease-associated mutation T119P in Norrin would also be expected to disrupt Norrin folding, but other clinically relevant Norrin mutations at positions R115 and R121 likely exert their influence by disrupting the Norrin-Tspan12 interface. Using mechanistic models of other cell-surface modulators of Wnt/β-catenin signaling as a starting point, we probed how the direct Tspan12-Norrin interaction might promote Norrin/β-catenin signaling.</p><sec id="s3-1"><title>Tspan12 captures Norrin upstream of signaling</title><p>Tspan12 has been proposed to enhance Norrin-Fzd4 affinity, supported initially by findings that Tspan12 rescues Norrin cell-surface binding and Norrin-stimulated signaling in cells when mutations disrupt the Norrin-Fzd4 interface (<xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>). We now have shown that Tspan12 also enhances binding of Norrin to Fzd4-containing nanodiscs and Fzd4-expressing cells. This effect is most evident at very low concentrations of Norrin, which could explain why previous experiments using Norrin-conditioned media did not show Tspan12-mediated differences in cell-surface Norrin binding (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>). Tspan12 might facilitate the Norrin-Fzd4 interaction by (1) increasing the number of cell-surface binding sites for Norrin and thereby increasing the local concentration of Norrin, similar to a proposed role for HSPGs in signaling through Wnt (<xref ref-type="bibr" rid="bib3">Baeg et al., 2001</xref>; <xref ref-type="bibr" rid="bib60">Reichsman et al., 1996</xref>) or (2) serving as a cofactor that forms a complex with Fzd4 and Norrin to increase Norrin-Fzd4 affinity, similar to a proposed role of heparin, which increases Norrin capture by Fzd4 in ELISA (<xref ref-type="bibr" rid="bib68">Smallwood et al., 2007</xref>). On the basis that the Fzd4 CRDL and Tspan12 bind Norrin with negative cooperativity, we propose that Tspan12 does not directly enhance Norrin-Fzd4 affinity. Rather, it enhances Norrin capture and increases local Norrin concentration. As Tspan12 co-localizes with Fzd4 on the cell surface (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>), Tspan12 can hand off captured Norrin to nearby Fzd4 for signaling, a process facilitated by the negative cooperativity of Norrin-Fzd4 and Norrin-Tspan12 binding.</p><p>In addition to co-localizing with Fzd4, Tspan12 has been shown to co-localize with the Fzd4-Norrin-LRP5 signaling complex at the cell surface and in endosomes (<xref ref-type="bibr" rid="bib98">Zhang et al., 2017</xref>). Yet, we found that Tspan12 competes with LRP6 for Norrin binding, suggesting that Tspan12 does not remain bound to Norrin in a quaternary complex with Fzd4 and LRP5/6 co-receptors. These results do not preclude the possibility that Tspan12 might incorporate into the signalosome by interacting with Fzd4 even after passing off Norrin. Alternatively, Tspan12 and LRP5/6 may each bind one Norrin protomer and thus be bridged as a complex through Norrin dimerization, averting the need for complete dissociation of Tspan12, a potentially inefficient process since Norrin binds Tspan12 with a relatively high affinity even in the presence of Fzd4.</p><p>Within the signalosome, Tspan12 could enhance Norrin-stimulated signaling by promoting downstream interactions like Dvl recruitment by Fzd. However, we found that Tspan12 did not affect Fzd4 affinity for the Dvl2 DEP domain in the absence of Norrin, nor did Tspan12 allow Norrin to allosterically enhance Fzd4-DEP affinity. These observations suggest that Tspan12 exerts its influence on Norrin/β-catenin signaling primarily by enhancing extracellular ligand capture, but we cannot rule out the possibility that Tspan12 may aid in Dvl recruitment by binding other regions of Dvl. An alternative, untested mechanism may involve Tspan12-mediated recruitment or activation of phosphoinositide kinases such as PI4KIIα, which binds other tetraspanins (<xref ref-type="bibr" rid="bib6">Berditchevski et al., 1997</xref>; <xref ref-type="bibr" rid="bib93">Yauch et al., 1998</xref>; <xref ref-type="bibr" rid="bib94">Yauch and Hemler, 2000</xref>) and is required for Wnt-stimulated PIP<sub>2</sub> generation that enhances Dvl recruitment to Fzd and subsequent LRP5/6 phosphorylation (<xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Pan et al., 2008</xref>).</p><p>Overall, our results are consistent with a model in which Tspan12 captures Norrin and hands it off like a baton to Fzd4 before formation of the Fzd4-Norrin-LRP5/6 complex (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Thus, the observed effects of Tspan12 on Norrin/β-catenin signaling are driven by a Tspan12-dependent increase in the local concentration of Norrin, which provides avidity to enhance the efficiency of Fzd4-Norrin-LRP5/6 complex formation at low Norrin concentrations.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Diverse co-receptors facilitate growth factor signaling by capturing and delivering ligands to their target receptors.</title><p>(<bold>A</bold>) Model: Norrin is captured by Tspan12 or heparan sulfate proteoglycans (HSPGs) and is handed off to Fzd4 for association with LRP5/6 and subsequent signaling. Norrin binding to cell-surface Fzd4 is enhanced when HSPGs concentrate Norrin at the cell surface. In contrast, Tspan12 directly and specifically delivers Norrin to co-localized Fzd4. (<bold>B</bold>) In the β-catenin signaling pathway, <italic>Left:</italic> Tspan12 captures Norrin and co-localizes with Fzd4, delivering Norrin to Fzd4. <italic>Middle:</italic> Likewise, RECK binds Wnt7a/b and co-localizes with Fzd via GPR124, delivering Wnt7a/b to Fzd. <italic>Right:</italic> Glypican-3 (GPC3) also binds both Fzd and Wnt to deliver Wnt to Fzd and enhance signaling. (<bold>C</bold>) Structurally diverse co-receptors play a similar role to Tspan12 in various pathways activated by cystine knot growth factors. <italic>Left:</italic> Neuropilin-1 (Nrp1) captures vascular endothelial growth factor A (VEGF) and co-localizes with the VEGF receptor 2 (VEGFR2) to specifically deliver VEGF to VEGFR2. <italic>Middle:</italic> The repulsive guidance molecule (RGM) binds bone morphogenic protein 2 (BMP2) as well as neogenin-1 (Neo1) to facilitate BMP signaling. <italic>Right:</italic> Betaglycan captures transforming growth factor β1 (TGF-β) and presents it to TGF-β receptor type 2 (TGFβR2).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96743-fig6-v1.tif"/></fig><p>Such a mechanism may represent a more general theme among modulators that enhance Wnt/β-catenin signaling (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The co-receptor Gpr124 similarly co-localizes with Fzd (<xref ref-type="bibr" rid="bib2">America et al., 2022</xref>; <xref ref-type="bibr" rid="bib24">Eubelen et al., 2018</xref>) and captures Wnt7a/7b through RECK, thereby delivering Wnt to Fzd. The HSPG Glypican-3 also binds both Fzd and Wnt to enhance signaling (<xref ref-type="bibr" rid="bib10">Capurro et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Li et al., 2019</xref>). Interestingly, these systems rely on both Wnt and Fzd binding to function: RECK without Gpr124 captures Wnt7a/b but does not deliver it to Fzd and does not mediate signaling enhancement on its own (<xref ref-type="bibr" rid="bib2">America et al., 2022</xref>; <xref ref-type="bibr" rid="bib14">Cho et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Eubelen et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Vallon et al., 2018</xref>). Likewise, Glypican-6, which can bind Wnt but not Fzd, does not promote Wnt signaling (<xref ref-type="bibr" rid="bib10">Capurro et al., 2014</xref>). Similarly, Tspan12 likely enhances signaling through its ability to both bind Norrin and co-localize with Fzd4 on the cell surface, thus promoting the formation of a Norrin-Fzd4 complex. However, the question of how Tspan12 co-localizes with Fzd4 remains to be addressed.</p><p>Outside of Wnt signaling, various other growth factors are controlled by the same mechanism: co-receptors for vascular endothelial growth factor A, bone morphogenic protein, and transforming growth factor β bridge these ligands and their receptors to enhance signaling (<xref ref-type="bibr" rid="bib27">Healey et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Hinck et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">López-Casillas et al., 1993</xref>; <xref ref-type="bibr" rid="bib69">Soker et al., 2002</xref>; <xref ref-type="fig" rid="fig6">Figure 6C</xref>). Interestingly, these ligands share the same cystine knot fold as Norrin, and similarly dimerize or oligomerize their cognate receptors to initiate signaling.</p><p>It has previously been proposed that Tspan12 directly enhances Fzd4-Fzd4 (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>) or Fzd4-LRP5 (<xref ref-type="bibr" rid="bib35">Knoblich et al., 2014</xref>) interactions. These models were supported by co-IP data and bolstered by observations that tetraspanins cluster in membrane nanodomains with their binding partners (<xref ref-type="bibr" rid="bib101">Zuidscherwoude et al., 2015</xref>). According to such a model, Tspan12-mediated clustering or localization of Fzd4 would be expected to enhance not only Norrin- but also Wnt-mediated signaling, which it does not (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>; <xref ref-type="bibr" rid="bib98">Zhang et al., 2017</xref>; <xref ref-type="fig" rid="fig5">Figure 5F</xref>). This can be reconciled if Tspan12-mediated receptor clustering is Norrin-dependent: e.g., a Tspan12-rich membrane domain may capture Norrin to establish a high local Norrin concentration and consequently nucleate or stabilize clusters of Norrin-Fzd4 complexes and enable Fzd4-LRP5/6 crosslinking.</p><p>Tspan12 and Fzd4 exist as ligand-independent homodimers, heterodimers, and possibly larger oligomeric clusters in the membrane (<xref ref-type="bibr" rid="bib34">Ke et al., 2013</xref>), but due to the split GFP reconstitution strategy utilized in this study our results do not capture Tspan12’s role in the context of a putative receptor multimer with higher-order stoichiometry (e.g., 2:2 Tspan12:Fzd4). Our reconstituted system also may not capture physiological receptor phosphorylation or other post-translational modifications that could be necessary for Tspan12 to exert a direct role in Fzd4-Norrin or Fzd4-Dvl binding. Additionally, the lipid composition, membrane fluidity, and membrane curvature that these receptors encounter in the cell membrane are not fully recapitulated in nanodiscs and could be important for Tspan12 function. Due to these limitations, further experiments conducted in cells will be required to examine the predictions of our model in the context of physiological receptor stoichiometry, post-translational modifications, and plasma membrane environment.</p></sec><sec id="s3-2"><title>Tspan12 expression dictates specificity of Norrin/β-catenin signaling</title><p>The sensitivity of Norrin/β-catenin signaling to Tspan12 levels (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) underscores Tspan12 expression as a mechanism by which cell response to secreted Norrin can be tuned. As such, it provides a strategy to spatiotemporally regulate development. For example, in the retina, Tspan12 is expressed in vascular endothelial cells while Fzd4 and LRP5 are more broadly expressed (<xref ref-type="bibr" rid="bib33">Junge et al., 2009</xref>). Consequently, Tspan12 expression dictates which cells preferentially bind and respond to Norrin, thereby directing proper angiogenesis.</p><p>Overcoming on-target toxicity in off-target tissues presents a major challenge in therapeutically targeting the Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib19">Diamond et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Tabernero et al., 2023</xref>), as systemically administered drugs do not benefit from the spatial specificity of endogenous ligands, whose expression varies by tissue and cell type (<xref ref-type="bibr" rid="bib46">Murphy et al., 2022</xref>; <xref ref-type="bibr" rid="bib59">Rawal et al., 2006</xref>; <xref ref-type="bibr" rid="bib72">Summerhurst et al., 2008</xref>). Tspan12 and other co-receptors can serve as specific drug targets, as well as mechanistic inspiration, for the development of new ligand- and tissue-specific therapies. Targeting pathway modulators that have restricted expression patterns would achieve spatial specificity by limiting therapeutic activity to a select subset of tissues (<xref ref-type="bibr" rid="bib15">Chouinard et al., 2016</xref>). More broadly, a mechanistic understanding of Wnt/β-catenin pathway modulators like Tspan12 could inspire the development of therapeutics to inhibit or activate the pathway in a cell- and tissue-specific manner.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">untagged Tspan12</td><td align="left" valign="bottom">DNASU</td><td align="left" valign="bottom">Clone HsCD00045716</td><td align="left" valign="bottom">Subcloned into pTT5 vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Tspan12∆C (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">pVL1393 vector; residues 1–252; Rho-1D4-tagged</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Tspan12 (full-length, human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216381">Addgene_216381</ext-link></td><td align="left" valign="bottom">pTT5 vector; Rho-1D4 tagged; deposited at Addgene (#216381)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Tspan12-LEL11 (human)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28658627/">28658627</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Rho-1D4-tagged and subcloned into pVL1393 vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Tspan12LEL (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216383">Addgene_216383</ext-link></td><td align="left" valign="bottom">pAcGP67a vector; residues 118–218; MBP-tagged; Deposited at Addgene (#216383)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Fzd4 (mouse)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35998232/">35998232</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216378">Addgene_216378</ext-link></td><td align="left" valign="bottom">pFastBac1 vector; residues 42–537; FLAG-tagged; Deposited at Addgene (#216378)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HA-FLAG-Fzd4∆C-3C-GFP1-10OPT-ETVV (mouse)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35074428/">35074428</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216380">Addgene_216380</ext-link></td><td align="left" valign="bottom">pVL1393 vector; residues 42–513; Deposited at Addgene (#216380)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Tspan12∆C-His-3C-GFP11 (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216382">Addgene_216382</ext-link></td><td align="left" valign="bottom">pVL1393 vector; residues 1–252; Deposited at Addgene (#216382)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">LRP6 (human)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35074428/">35074428</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">pEZT-BM vector; residues 20–1439; FLAG-tagged</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">LRP6 E1E2 (human)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22000856/">22000856</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">pAcGP67a vector; 10xHis-tagged</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MESD (human)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35074428/">35074428</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">pEZT-BM vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Norrin (human)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35074428/">35074428</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216384">Addgene_216384</ext-link></td><td align="left" valign="bottom">pAcGP67a vector; residues 33–133; MBP- and Rho-1D4 tags; Deposited at Addgene (#216384)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Monomeric Norrin</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216386">Addgene_216386</ext-link></td><td align="left" valign="bottom">pAcGP67a vector; residues 33–133; MBP- and Rho-1D4-tagged; C93A/C95A/C131A; Deposited at Addgene (#216386)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Fzd4 CRDL (mouse)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30104375/">30104375</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216379">Addgene_216379</ext-link></td><td align="left" valign="bottom">pAcGP67a vector; residues 42–203; 6xHis-tagged; Deposited at Addgene (#216379)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">DEP (DEP domain from mouse Dvl2)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35998232/">35998232</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_216386">Addgene_216386</ext-link></td><td align="left" valign="bottom">pCDF vector; residues 416–510; MBP-tagged; Deposited at Addgene (#216386)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">GFP nanobody</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/20945358/">20945358</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">pET26(+) vector; with pelB signal sequence and 6xHis tag</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSP1D1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_20061">Addgene_20061</ext-link></td><td align="left" valign="bottom">Sligar lab</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSP1E3D1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_20066">Addgene_20066</ext-link></td><td align="left" valign="bottom">Sligar lab</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EZ-link NHS-PEG4-Biotin</td><td align="left" valign="bottom">Thermo</td><td align="left" valign="bottom">Cat. #: A39259</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">16:0–18:1 phosphatidyl choline (POPC)</td><td align="left" valign="bottom">Avanti Polar Lipids</td><td align="left" valign="bottom">Cat. #: 850457</td><td align="left" valign="bottom">For nanodisc reconstitution (see Materials and methods section)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">16:0–18:1 phosphatidylglycerol (POPG)</td><td align="left" valign="bottom">Avanti Polar Lipids</td><td align="left" valign="bottom">Cat. #: 840457</td><td align="left" valign="bottom">For nanodisc reconstitution (see Materials and methods section)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">18:0–20:4 brain phosphatidylinositol-4,5-bisphosphate (PIP2)</td><td align="left" valign="bottom">Avanti Polar Lipids</td><td align="left" valign="bottom">Cat. #: 840046</td><td align="left" valign="bottom">For nanodisc reconstitution (see Materials and methods section)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rho anti-1D4 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnologies</td><td align="left" valign="bottom">Cat. #: sc-57432; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_785511">AB_785511</ext-link></td><td align="left" valign="bottom">(0.5 µg/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">THE anti-His (mouse monoclonal)</td><td align="left" valign="bottom">GenScript</td><td align="left" valign="bottom">Cat. #: A00186; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_914704">AB_914704</ext-link></td><td align="left" valign="bottom">(0.33 µg/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">M1 anti-FLAG (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: F3040; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_439712">AB_439712</ext-link></td><td align="left" valign="bottom">(0.5 µg/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 800 goat anti-mouse secondary</td><td align="left" valign="bottom">LI-COR</td><td align="left" valign="bottom">Cat. #: 926–32210; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_621842">AB_621842</ext-link></td><td align="char" char="." valign="bottom">(1:15,000)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Dylight Neutravidin-800</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: 22853</td><td align="char" char="." valign="bottom">(1:10,000)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">CNBr-activated sepharose</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat. #: 17043001</td><td align="left" valign="bottom">To generate GFP nanobody resin (see Materials and methods section)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Streptavidin paramagnetic particles</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat. #: Z5481</td><td align="left" valign="bottom">For bead binding competition experiments (see Materials and methods section)</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">BL21(DE3)-RIL</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat. #: 230245</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Spodoptera frugiperda</italic>)</td><td align="left" valign="bottom">Sf9 cells</td><td align="left" valign="bottom">Expression Systems</td><td align="left" valign="bottom">Cat. #: 94-001F; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0549">CVCL_0549</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">Expi293 cells</td><td align="left" valign="bottom">Thermo</td><td align="left" valign="bottom">Cat. #: A14527; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_D615">CVCL_D615</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">Freestyle293 cells</td><td align="left" valign="bottom">Thermo</td><td align="left" valign="bottom">Cat. #: R79007; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_D603">CVCL_D603</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">HEK293T cells (Fzd1/2/4/5/7/8 KO)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28733458/">28733458</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Boutros lab</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tspan12 siRNA duplex #1</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: VC30002</td><td align="left" valign="bottom">5’-GCUUAUCUUUGCCUUCUCCTT-3’ and 5’-<named-content content-type="sequence">GGAGAAGGCAAAGA</named-content>UAAGCTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tspan12 siRNA duplex #2</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: VC30002</td><td align="left" valign="bottom">5’-AUGAGGGACUACCUAAAUATT-3’ and 5’-UAUUUAGGUAGUCCCUCAUTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Control siRNA</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: SIC001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Super8xTOPFLASH</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_12456">Addgene_12456</ext-link></td><td align="left" valign="bottom">Moon lab</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dual-Light reporter assay system</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat. #: T1005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom">GraphPad Software, LLC</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">AlphaFold2</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34265844/">34265844</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_025454">SCR_025454</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">AlphaFold Multimer v2</td><td align="left" valign="bottom">DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2021.10.04.463034">10.1101/2021.10.04.463034</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ColabFold</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35637307/">35637307</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_025453">SCR_025453</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ChimeraX 1.6</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28710774/">28710774</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_015872">SCR_015872</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cryoSPARC v4</td><td align="left" valign="bottom">Structura Biotechnology</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016501">SCR_016501</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines</title><p>HEK293T cells with Fzd1/2/4/5/7/8 knocked out were provided by Michael Boutros, who authenticated the parental HEK293T cell line by single nucleotide polymorphism-based authentication (<xref ref-type="bibr" rid="bib84">Voloshanenko et al., 2017</xref>). Freestyle293 cells (Thermo), Expi293 cells (Thermo), and Sf9 cells (Expression Systems) were purchased directly from vendors who provided a certificate of analysis, so we have not sent these cells for authentication. All four cell lines tested negative for mycoplasma contamination via PCR (abm).</p></sec><sec id="s4-2"><title>Protein constructs, expression, and purification</title><p>Human Tspan12 (DNASU) truncated after the fourth transmembrane domain (∆C, residues 1–252) and Tspan12 with the LEL replaced by that of TSPAN11 (Tspan12-LEL11, Addgene plasmid #115785 from Harald Junge; <xref ref-type="bibr" rid="bib37">Lai et al., 2017</xref>) were C-terminally tagged with the Rho-1D4 antibody recognition sequence TETSQVAPA. Full-length Tspan12 (1-305) and derived point mutants, also with a C-terminal TETSQVAPA, were cloned into pTT5 (NRC) for purification from Expi293 cells. Mouse Fzd4 (42–537) and human LRP6 (20–1439) were preceded by an N-terminal hemagglutinin signal peptide (HA<sub>sp</sub>) followed by FLAG tag. For the split GFP tethered dimers (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>), the sequence of HA<sub>sp</sub>-FLAG-mFzd4∆C(42-513) was followed by a 1x GS linker, the HRV 3C recognition sequence, a 1x GGTS linker, the split GFP 1–10 OPT sequence engineered by the Waldo group (<xref ref-type="bibr" rid="bib9">Cabantous et al., 2005</xref>), a gift from Steven Boxer (<xref ref-type="bibr" rid="bib18">Deng and Boxer, 2018</xref>), a 2x GS linker, and the C-terminal PDZ ligand from Fzd4 (sequence ETVV). Tspan12∆C (1–252) was followed by a 6xHis tag, a 1x GS linker, the HRV 3C recognition sequence, a 2x GS linker, and the GFP 11 M3 sequence (<xref ref-type="bibr" rid="bib9">Cabantous et al., 2005</xref>). Tspan12∆C-1D4, Tspan12-LEL11-1D4, HA-FLAG-Fzd4, HA-FLAG-Fzd4∆C-3C-GFP1-10OPT-ETVV, and Tspan12∆C-His-3C-GFP11 were inserted into pVL1393 (Expression Systems) or pFastBac1 (Invitrogen) by Gibson Assembly (New England Biolabs) for expression in insect cells. LRP6 and its chaperone MESD were inserted into the pEZT-BM vector (Addgene #74099) for expression in Freestyle293 cells. The Tspan12 LEL (residues 118–218), N-terminally tagged with maltose binding protein and the 3C protease recognition sequence, was inserted into the pAcGP67a transfer vector (BD Biosciences). Virus was produced and amplified according to the manufacturer’s instructions.</p><p>For protein expression, all lysis, wash, and affinity column buffers included the protease inhibitors 0.15 µM aprotinin, 1 μM E-64, and 1 µM leupeptin, and 200 µM phenylmethylsulfonyl fluoride. Buffers for constructs including the transmembrane domain additionally included 60 µM <italic>N</italic>-<italic>p</italic>-Tosyl-L-phenylalanine chloromethyl ketone and 60 µM <italic>N</italic><sub>α</sub>-Tosyl-L-lysine chloromethyl ketone. All steps were performed at 4°C.</p><p>For receptor preparations of Tspan12, Fzd4, and Tspan12/Fzd4-sGFP, Sf9 cells (Expression Systems) were infected at a density of 3×10<sup>6</sup> cells/mL with 1:300 vol/vol virus and harvested after 48 hr. WT and mutant Tspan12 were produced for binding studies in Expi293 cells transfected with PEIpro (Polyplus) according to the manufacturer’s instructions, enhanced 16 hr later with 10 mM sodium butyrate (Sigma), and harvested 48 hr post-transfection. Sf9 or Expi293 cells were lysed using nitrogen cavitation (Parr Instrument Company) at 650 psi for 30 min in 20 mM HEPES pH 8.0, 65 mM NaCl (for Sf9) or 10 mM NaCl (for Expi293), 1 mM EDTA, and 10 mM iodoacetamide. Nuclei and cell debris were pelleted at 1000 × <italic>g</italic> for 15 min, and the resulting supernatant was centrifuged at 200,000 × <italic>g</italic> in an ultracentrifuge for 40 min. Pelleted membranes were Dounce homogenized 30× to resuspend into high-salt buffer (50 mM HEPES pH 8, 300 mM NaCl) and centrifuged at 200,000 × <italic>g</italic> for 40 min. Membranes were Dounce homogenized 30× into low-salt buffer (50 mM HEPES pH 8, 100 mM NaCl) and frozen dropwise in liquid nitrogen, then stored at –80°C until use.</p><p>Tspan12 membranes were thawed and adjusted to 5mg/mL protein (determined by Bradford assay), 20mM HEPES 8, 100mM NaCl, 10% (vol/vol) glycerol, 2.5mM EGTA, 2.5mM EDTA, 1% (wt/vol) <italic>n</italic>-dodecyl-β-D-maltopyranoside (DDM; Anatrace), 0.1% (wt/vol) GDN (Anatrace), and 0.1% (wt/vol) cholesteryl hemisuccinate (CHS; Anatrace). The membranes were stirred for 2hr at 4°C, then centrifuged at 200,000× <italic>g</italic> for 1hr. The supernatant was filtered through a 0.2µm filter prior to loading onto Rho-1D4 antibody resin (2mL resin per L culture), and beads were washed by gravity with 5 column volumes (CVs) each of 20mM HEPES pH 8, 1mM EDTA, 5% glycerol, plus (a) 300mM NaCl, 0.07% DDM, 0.007% CHS, 0.03% GDN; (b) 100mM NaCl, 0.04% DDM, 0.004% CHS, 0.06% GDN; (c) 100mM NaCl, 0.01% DDM, 0.001% CHS, 0.09% GDN; (d) 100mm NaCl, 0.1% GDN. The column was washed with one CV of elution buffer (20mM HEPES pH 8, 100mM NaCl, 1mM EDTA, 10% glycerol, 0.02% GDN, 200µM TETSQVAPA peptide [GenScript]), capped, and batch eluted rotating overnight with 1 additional CV elution buffer at 4°C. Eluate was collected 16hr later, concentrated in a 30kDa cutoff concentrator (Amicon) and further purified by size exclusion on a Superose 6 increase 10/300 column (Cytiva) in 20mM HEPES pH 8, 100mM NaCl, 1mM EDTA, 5% glycerol, 0.01% GDN. Analysis by SDS-PAGE informed pooling of pure, monomeric fractions, which were concentrated to 2–5mg/mL and frozen at –80°C.</p><p>Fzd4 and Tspan12/Fzd4 split-GFP were purified as above and as previously described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>). Briefly, the purification is similar to that detailed above with the following modifications: M1 anti-FLAG resin was used instead of 1D4 resin; binding and wash buffers did not contain EDTA or EGTA and were supplemented with 3 mM CaCl<sub>2</sub>, and elution buffer instead contained DYKDDDDK peptide (GenScript) and 5 mM EGTA. Additionally, for LRP6 and Fzd4 alone, wash and elution buffers did not contain glycerol or EDTA, and receptor was not exchanged into GDN (all wash buffers contained 0.1% DDM and 0.001% CHS; elution and SEC buffers contained 0.03% DDM and 0.003% CHS).</p><p>FLAG-LRP6(20–1439) was co-expressed in Freestyle293 cells with the chaperone MESD and purified as previously described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>). Briefly, the purification is similar to FLAG-tagged Fzd4 above with the following modifications: after binding, the anti-FLAG resin was washed with 10 CVs of low pH buffer (50 mM sodium acetate [pH 5.0], 150 mM NaCl, 0.1% DDM, 0.01% CHS, and 2 mM CaCl<sub>2</sub>) to remove bound MESD, and 10 CVs of ATP wash (low salt buffer supplemented with 5 mM ATP, 20 mM MgCl<sub>2</sub>, and 50 mM KCl) to remove bound HSP 70, before elution with DYKDDDDK peptide and EGTA as above. The final SEC buffer included 2 mM CaCl<sub>2</sub> instead of EDTA.</p><p>MBP-3C-Norrin(33–133)-1D4 (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>), Fzd4 extracellular domain (CRD and linker, residues 42–203, C-terminally His<sub>6</sub>-tagged) (<xref ref-type="bibr" rid="bib4">Bang et al., 2018</xref>) and LRP6 E1E2 (residues 20–630, C-terminally His<sub>10</sub>-tagged) (<xref ref-type="bibr" rid="bib1">Ahn et al., 2011</xref>) in the (BD Biosciences) transfer vector were purified from baculovirus-infected Sf9 cells according to the previously published works. For binding experiments, purified MBP-3C-Norrin was biotinylated with EZ-link NHS-PEG4-Biotin (Thermo) at 1:1 molar ratio and re-purified by SEC. Monomeric Norrin (MBP-3C-Norrin C93A/C95A/C131A) was purified identically to dimeric Norrin (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). MBP-tagged Tspan12 LEL, also in pAcGP67, was purified similarly in the same buffer (20 mM HEPES pH 8, 300 mM NaCl, 1 mM EDTA, 5% glycerol). For untagged LEL, the LEL was eluted from the amylose resin with 3C protease and minimally concentrated before injection onto a HiLoad 26/600 Superdex 200 pg column (Cytiva). Pooled fractions were concentrated in a 3 kDa cutoff spin concentrator (Amicon) to 0.3 mg/mL for storage at –80°C.</p><p>The purification of MBP-tagged DEP domain of mouse Dishevelled2 (residues 416–510) from BL21(DE3)-RIL cells was performed as previously described (<xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>).</p><p>The His<sub>6</sub>-tagged GFP nanobody sequence (<xref ref-type="bibr" rid="bib36">Kubala et al., 2010</xref>) was cloned into pET26(+), expressed in the periplasm of <italic>E. coli</italic> BL21(DE3)-RIL, and purified according to previously published protocols (<xref ref-type="bibr" rid="bib55">Pardon et al., 2014</xref>). The nanobody was coupled to CNBr-activated Sepharose (Cytiva) according to the manufacturer’s instructions.</p><p>His<sub>6</sub>-tagged MSP1D1 and MSP1E3D1 (Addgene plasmids #20061 and #20066) were expressed in <italic>E. coli</italic> BL21(DE3)-RIL and purified (<xref ref-type="bibr" rid="bib5">Bayburt et al., 2002</xref>; <xref ref-type="bibr" rid="bib62">Ritchie et al., 2009</xref>) and biotinylated using EZ-link NHS-PEG4-Biotin (Thermo) as previously described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>).</p></sec><sec id="s4-3"><title>Nanodisc reconstitution</title><p>Receptors were inserted into nanodiscs as previously described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>; <xref ref-type="bibr" rid="bib62">Ritchie et al., 2009</xref>; <xref ref-type="bibr" rid="bib88">Whorton et al., 2007</xref>). Briefly, lipids (16:0-18:1 phosphatidyl choline [POPC], 16:0–18:1 phosphatidylglycerol (POPG) and 18:0-20:4 brain phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>), Avanti Polar Lipids) and cholesterol (Sigma) were purchased pre-dissolved in organic solvent, and opened stocks were stored under argon at –20°C for &lt;3 months (POPC, POPG, PIP<sub>2</sub>) or &lt;1 month (cholesterol). Lipids were mixed at a 48:32:20 POPC:POPG:cholesterol (or 75:5:20 POPC:PIP<sub>2</sub>:cholesterol, for DEP binding [<xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>]) molar ratio and dried under a stream of argon and then under vacuum for 1 hr. Dried lipids were resuspended in HNE (20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM EDTA) supplemented with 50 mM sodium cholate. HNE buffer, receptor, and MSP were added to reach final concentrations of 18 mM sodium cholate, 6 mM lipid, 0.1 mM MSP1D1 or 0.07 mM MSP1E3D1, and 5 µM receptor monomer or receptor dimer. After incubation on ice for 1 hr, detergent was removed with Bio-Beads (Bio-Rad, 83 mg beads per nmol of lipids) overnight at 4°C.</p><p>Nanodiscs were further purified by size exclusion (Superose 6 Increase 10/300, Cytiva) in HNE buffer followed by M1 anti-FLAG (Fzd4), Rho anti-1D4 (Tspan12), or GFP nanobody (Tspan12/Fzd heterodimer; eluted with 3C protease) affinity chromatography. Wash and elution buffer for preparative samples consisted of HNE+0.1% bovine serum albumen (BSA; Sigma). BSA was omitted to enable clear analysis by SDS-PAGE (i.e., in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>).</p><p>The eluted nanodiscs were run on SDS-PAGE along with a standard curve of known amounts of MSP, and concentration was thus quantified using densitometry in ImageJ. Nanodiscs were stored on ice for up to 2 weeks.</p><p>For stoichiometry measurements, the concentration of MSP and receptor within each relevant sample was determined by quantitative western blot as described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>). Briefly, serial dilutions of reference proteins alongside nanodisc samples, diluted to be within the linear range of detection for the blotted protein, were loaded on SDS-PAGE gels and transferred to nitrocellulose. For Tspan12 receptor alone in nanodiscs, 0.04–0.32 picomoles of Tspan12-1D4 and 0.25–2 picomoles of 7xHis-MSP1D1 were probed by Rho anti-1D4 and THE anti-His (GenScript) antibodies respectively. For the Tspan12/Fzd4 heterodimer, 0.125–1 picomoles of Tspan12-6xHis, 0.01–0.08 picomoles of FLAG-Fzd4 were probed by THE anti-His (GenScript) and M1 anti-FLAG antibodies, respectively; and 0.25–2 picomoles of MSP1D1-biotin was detected by DyLight 800-conjugated Neutravidin (Invitrogen), as His-tagged 3C protease runs similarly to MSP1D1 on a gel. All other samples were detected with IRDye 800 Goat-anti Mouse IgG (LI-COR). For each of the two nanodisc species (Tspan12 alone and Tspan12/Fzd4 heterodimer), all proteins within three independently reconstituted samples were measured three times each in separate western blots.</p></sec><sec id="s4-4"><title>Biolayer interferometry</title><p>Kinetic and steady-state binding affinities were measured by BLI as previously described (<xref ref-type="bibr" rid="bib8">Bruguera et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Mahoney et al., 2022</xref>) using Octet RED384 (Sartorius) or GatorPrime (Gator Bio) instruments at 25°C at 1000 rpm shaking, in 20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% BSA. Binding buffer for experiments that included LRP6 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>) also included 3 mM CaCl<sub>2</sub>. Binding experiments between soluble proteins only (i.e., the Tspan12 LEL and Norrin, ±CRDL) additionally included 0.05% Tween 20 to minimize non-specific binding. Streptavidin-coated biosensors were loaded with 20 nM biotinylated nanodiscs for 5 min (yielding an interference shift between 1.5 and 2.5 nm) prior to binding.</p><p>For Norrin-binding experiments, 100 nM MBP-Norrin in binding buffer was incubated with 3C protease for 30 min at room temperature to cleave the MBP tag before binding. SOS (potassium salt) was obtained from Santa Cruz Biotechnology. For DEP binding in the presence of Norrin, biosensor-immobilized Fzd4±Tspan12 receptors were pre-bound to 10 nM Norrin for 30 min before DEP binding was conducted in buffer containing 10 nM Norrin.</p><p>After preliminary processing (Savitzky-Golay filtering, signal subtraction of control conditions, i.e., ligand binding to receptor-less nanodiscs, which was run in parallel) in the Octet Data Analysis 10.0 or Gator 1.7 software, curve fitting was performed in Prism (GraphPad). Steady-state binding affinity values and Hill slopes were obtained by fitting equilibrium data (signal plateau value) to a one-site model of specific binding with variable Hill slope. When multiple concentrations of analyte were measured, the association rate constant K<sub>on</sub> was determined as the slope of the line fit through a plot of the observed association rate constant (K<sub>obs</sub>, obtained from one-phase exponential association fits to each association trace) vs. ligand concentration. Dissociation traces were fit to one-phase exponential decay curves to obtain the dissociation rate constant K<sub>off</sub>, and the mean K<sub>off</sub> was calculated using dissociation data for which the R<sup>2</sup> was &gt;0.8 (i.e., discarding the low concentration conditions with low signal). For experiments in which only one ligand concentration was measured (i.e., mutant Tspan12 and Norrin-binding measurements in <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>, and <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>), the K<sub>on</sub> and K<sub>off</sub> were determined using the ‘Association then dissociation’ model in Prism.</p><p>Each binding experiment was performed in triplicate, using at least two independent preparations each of receptor and ligand.</p></sec><sec id="s4-5"><title>AlphaFold predictions</title><p>The sequence for Tspan12 (full-length) alone or with one or two copies of Norrin (residues 25–133) were input into AlphaFold 2 (<xref ref-type="bibr" rid="bib32">Jumper et al., 2021</xref>) or AlphaFold Multimer v2 (<xref ref-type="bibr" rid="bib25">Evans et al., 2022</xref>) using ColabFold (<xref ref-type="bibr" rid="bib45">Mirdita et al., 2022</xref>) via ChimeraX (1.6, daily build from October 23, 2022) (<xref ref-type="bibr" rid="bib26">Goddard et al., 2018</xref>). The following PDB structures were used as templates for Tspan12: 6wvg_A, 6wvg_B, 6k4j_A, 5tcx_A, 7rdb_A, 7rdb_H, 2m7z_A, 6wvg_A, 6wvg_B; and for Norrin: 5bpu_A, 5bqe_B, 5bq8_A, 5aej_A, 4jph_B, 5hk5_F, 2kd3_A, 4nt5_A, 4x1j_B, 6l6r_C, 6l6r_D, 2k8p_A, 4x1j_A, 6p57_A, 7fih_Y, 5cl1_A, 4yu8_A, 4ay9_B, 4mqw_B, 4mqw_E. The top-ranked structure (sorted by pLDDT for Tspan12 alone, or pTMscore for Tspan12+Norrin complexes) was relaxed with Amber (<xref ref-type="bibr" rid="bib22">Eastman et al., 2017</xref>) and used for further studies.</p></sec><sec id="s4-6"><title>Bead binding competition experiments</title><p>Streptavidin paramagnetic particles (Promega), pre-equilibrated in wash buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.2% BSA), were pre-bound to Tspan12∆C (reconstituted in biotinylated MSP1D1) or receptorless nanodiscs. After 30 min at 25°C, the beads were quenched with biotin and washed three times with wash buffer. MBP-Norrin at 32 nM was premixed with 0, 0.1, 0.4, 1.6, 25, or 100 µM LRP6 E1E2 or Fzd4 CRDL and added to the beads, which were at a final concentration of 0.2 mg/mL paramagnetic particles and 50 nM Tspan12∆C; these conditions were chosen such that, in the absence of competitor, approximately half of the Norrin would be bound. Tubes were rotated for 16 hr at 4°C, then beads were washed three times with ice-cold wash buffer and protein was eluted with 1× non-reducing Laemmli sample buffer (non-reducing) at room temperature for 15 min. Three replicates per condition were loaded on an SDS-PAGE gel, transferred to nitrocellulose, and analyzed by western blot with anti-Rho 1D4 antibody, followed by goat anti-mouse 800 (LI-COR). Background-subtracted band intensities, which were verified to be in the linear range of detection using a standard curve loaded on the same gel, were quantified using Odyssey software (LI-COR). Data were analyzed in Prism (GraphPad) using the following system of equations (<xref ref-type="bibr" rid="bib85">Wang, 1995</xref>), which model the fraction of Norrin bound vs. competitor concentration (Fzd4 CRDL or LRP6 E1E2):</p><list list-type="simple"><list-item><p>h=KA +KB+A +X – R</p></list-item><list-item><p>k=[KB*(A-R)] + [KA*(X-R)] + (KA*KB)</p></list-item><list-item><p>l=-1*(KA*KB*R)</p></list-item><list-item><p>t=arccos[(–2*(h^3)+9*h*k - 27*l)/(2*sqrt((h^2–3k)^3))]</p></list-item><list-item><p>Y = [(2*(sqrt(h^2–3k))*(cos(t/3))-h)/(3*KA + (2*(sqrt(h^2–3k))*(cos(t/3))-h))]</p></list-item><list-item><p>where</p></list-item></list><list list-type="simple"><list-item><p>X=competitor concentration</p></list-item><list-item><p>Y=Norrin bound (as a fraction of total)</p></list-item><list-item><p>A=total Norrin binding sites = 64 nM</p></list-item><list-item><p>R=total Tspan12 concentration = 50 nM</p></list-item><list-item><p>KA = equilibrium Norrin-Tspan12 dissociation constant = 10.4 nM</p></list-item><list-item><p>KB=equilibrium Norrin-competitor dissociation constant (to be fit)</p></list-item><list-item><p>For experiments where only bead-bound Norrin was measured (instead of Bead+Sup, to obtain fraction bound), Y was normalized to the calculated fraction of Norrin bound in the absence of competitor, defined as (A+KA+R-sqrt((-A-KA-R)^2–4*A*R))/(2*A).</p></list-item></list><p>For modeling SOS-mediated inhibition of Norrin-Tspan12 binding assayed by BLI, the IC<sub>50</sub> was converted to K<sub>i</sub> using the Cheng-Prusoff equation.</p></sec><sec id="s4-7"><title>Negative stain electron microscopy</title><p>To analyze the oligomeric state of Norrin, MBP-Norrin (WT or C93A/C95A/C131A) was diluted to 100 nM in purification buffer (20 mM HEPES pH 8, 300 mM NaCl, 1 mM EDTA, 5% glycerol) and applied to glow-discharged CF-300Cu grids (Electron Microscopy Sciences), which were washed once with buffer (20 mM HEPES pH 8, 100 mM NaCl, 1 mM EDTA) and twice with 1% uranyl acetate stain before drying and imaging on a 100 kV Morgagni electron microscope equipped with an Orius CCD camera (Gatan) at 50,000×. Particle picking and 2D class averaging was performed in cryoSPARC v4 (Structural Biotechnology Inc).</p></sec><sec id="s4-8"><title>Cell-binding experiments</title><p>Expi293 cells (Thermo Fisher) were maintained in Expi293 media (Thermo Fisher) and transfected at a density of 3×10<sup>6</sup> cells/mL using ExpiFectamine293 (Thermo Fisher) according to the manufacturer’s instructions. Cells were transfected with untagged Tspan12 in pTT5 (NRC), FLAG-tagged Fzd4 in pcDNA3.1 (Thermo Fisher), or both Tspan12 and Fzd4 (300 ng each receptor per mL of cells), with additional empty vector to bring total DNA transfected to 1 µg/mL of cells. 48 hr post-transfection, cells were transferred to a 96-well v-bottom plate and incubated with 0, 0.032, 0.1, 0.32, 1, or 3.2 nM purified MBP-Norrin in binding buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.2% BSA) for 10 min at 23°C, shaking. Cells were collected by centrifugation and washed twice with binding buffer and incubated with Alexa Fluor 647-conjugated anti-rho 1D4 antibody in binding buffer for 15 min at room temperature. Cells were washed once with binding buffer and resuspended in PBS prior to detection with an Accuri C6 Plus flow cytometer (BD). Data were exported to Prism (GraphPad) for quantification of median fluorescence intensity and statistical analysis.</p></sec><sec id="s4-9"><title>β-Catenin transcriptional reporter assay and Fzd knockout cell line</title><p>HEK293T cells with Fzd1/2/4/5/7/8 knocked out (<xref ref-type="bibr" rid="bib84">Voloshanenko et al., 2017</xref>) were maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gemini). In a six-well plate, cells were seeded at 200,000 cells/well and immediately transfected with 30 picomoles of control siRNA (Sigma SIC001), or 15 picomoles each of two previously validated (<xref ref-type="bibr" rid="bib52">Otomo et al., 2014</xref>) Tspan12 siRNA duplexes (#1: 5’-<named-content content-type="sequence">GCUUAUCUUUGCCUUCUCCTT</named-content>-3’ and 5’-GGAGAAGGCAAAGAUAAGCTT-3’; #2: 5’-<named-content content-type="sequence">AUGAGGGACUACCUAAAUATT</named-content>-3’ and 5’-<named-content content-type="sequence">UAUUUAGGUAGUCCCUCAUTT</named-content>-3’) (Sigma) using Lipofectamine RNAiMax (Thermo Fisher) diluted in OptiMEM (Thermo Fisher) according to the manufacturer’s instructions, with media replaced after 16 hr. Two days post-transfection, cells were seeded at 12,000 cells/well in white 96-well plates (PerkinElmer) and transfected 4 hr later with receptor vectors in pcDNA (0.1 ng/well FLAG-Fzd4_pcDNA, untagged Tspan12_pTT5 amounts as indicated), Super8xTOPFLASH (Addgene plasmid #12456, 80 ng/well) and LacZ under a CMV promoter (20 ng/well) using Lipofectamine 2000 (Invitrogen). Media was replaced 16–20 hr later with DMEM alone or supplemented with purified Norrin, which was cleaved from MBP with 3C protease prior to addition to cells. Cells were lysed 22–26 hr later and assayed for luciferase and β-galactosidase activity using the Dual-Light system (Invitrogen) according to the manufacturer’s instructions on a BioTek Synergy2 plate reader. Luciferase signal was normalized to β-galactosidase signal; all TOPFLASH values are reported as fold change over the basal signal (defined as 0 ng Tspan12, 0 nM Norrin, in cells transfected with control siRNA).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Table of kinetic constants and steady-state affinities quantified by biolayer interferometry.</title></caption><media xlink:href="elife-96743-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96743-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source data files containing the numerical data used to generate figures 1-5 have been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>ESB was supported by an NIH predoctoral fellowship (F31 EY031947) and a Stanford Graduate Fellowship, and JPM was supported by an NIH postdoctoral fellowship (F32 GM126642). This work was supported by an NIH grant (R35 GM131747 to WW). We thank Roel Nusse, Sabine Pokutta, Kaavya Krishna Kumar, and Brian Kobilka of Stanford University, as well as Jon-Michael Knapp of Luminint Consulting, for comments on the manuscript. We thank Samantha Gumbin for advice on siRNA experiments. We are grateful to Liz Montabana of the Stanford Cryo-EM Center for assistance with electron microscopy, and to Sharon Pitteri and Abel Bermudez of the Canary Center Proteomics Resource Facility for access to BLI instrumentation.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>VE</given-names></name><name><surname>Chu</surname><given-names>MLH</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Tran</surname><given-names>D</given-names></name><name><surname>Abo</surname><given-names>A</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6</article-title><source>Developmental Cell</source><volume>21</volume><fpage>862</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2011.09.003</pub-id><pub-id pub-id-type="pmid">22000856</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>America</surname><given-names>M</given-names></name><name><surname>Bostaille</surname><given-names>N</given-names></name><name><surname>Eubelen</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Vanhollebeke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>An integrated model for Gpr124 function in Wnt7a/b signaling among vertebrates</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110902</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110902</pub-id><pub-id pub-id-type="pmid">35649360</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeg</surname><given-names>GH</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Khare</surname><given-names>N</given-names></name><name><surname>Baumgartner</surname><given-names>S</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless</article-title><source>Development</source><volume>128</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1242/dev.128.1.87</pub-id><pub-id pub-id-type="pmid">11092814</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Beaven</surname><given-names>AH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>S-B</given-names></name><name><surname>Lee</surname><given-names>GR</given-names></name><name><surname>Kan</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Im</surname><given-names>W</given-names></name><name><surname>Seok</surname><given-names>C</given-names></name><name><surname>Chung</surname><given-names>KY</given-names></name><name><surname>Choi</surname><given-names>H-J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biophysical and functional characterization of Norrin signaling through Frizzled4</article-title><source>PNAS</source><volume>115</volume><fpage>8787</fpage><lpage>8792</lpage><pub-id pub-id-type="doi">10.1073/pnas.1805901115</pub-id><pub-id pub-id-type="pmid">30104375</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayburt</surname><given-names>TH</given-names></name><name><surname>Grinkova</surname><given-names>YV</given-names></name><name><surname>Sligar</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Self-assembly of discoidal phospholipid bilayer nanoparticles with membrane scaffold proteins</article-title><source>Nano Letters</source><volume>2</volume><fpage>853</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1021/nl025623k</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berditchevski</surname><given-names>F</given-names></name><name><surname>Tolias</surname><given-names>KF</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Carpenter</surname><given-names>CL</given-names></name><name><surname>Hemler</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>2595</fpage><lpage>2598</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.5.2595</pub-id><pub-id pub-id-type="pmid">9006891</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourhis</surname><given-names>E</given-names></name><name><surname>Tam</surname><given-names>C</given-names></name><name><surname>Franke</surname><given-names>Y</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Ernst</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Cochran</surname><given-names>AG</given-names></name><name><surname>Hannoush</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>9172</fpage><lpage>9179</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.092130</pub-id><pub-id pub-id-type="pmid">20093360</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruguera</surname><given-names>ES</given-names></name><name><surname>Mahoney</surname><given-names>JP</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reconstitution of purified membrane protein dimers in lipid nanodiscs with defined stoichiometry and orientation using a split GFP tether</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>101628</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101628</pub-id><pub-id pub-id-type="pmid">35074428</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabantous</surname><given-names>S</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Waldo</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein</article-title><source>Nature Biotechnology</source><volume>23</volume><fpage>102</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nbt1044</pub-id><pub-id pub-id-type="pmid">15580262</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capurro</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Filmus</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling</article-title><source>Journal of Cell Science</source><volume>127</volume><fpage>1565</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1242/jcs.140871</pub-id><pub-id pub-id-type="pmid">24496449</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>T-H</given-names></name><name><surname>Hsieh</surname><given-names>F-L</given-names></name><name><surname>Zebisch</surname><given-names>M</given-names></name><name><surname>Harlos</surname><given-names>K</given-names></name><name><surname>Elegheert</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan</article-title><source>eLife</source><volume>4</volume><elocation-id>e06554</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.06554</pub-id><pub-id pub-id-type="pmid">26158506</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chidiac</surname><given-names>R</given-names></name><name><surname>Abedin</surname><given-names>M</given-names></name><name><surname>Macleod</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Thibeault</surname><given-names>PE</given-names></name><name><surname>Blazer</surname><given-names>LL</given-names></name><name><surname>Adams</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Roehrich</surname><given-names>H</given-names></name><name><surname>Jo</surname><given-names>HN</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Sidhu</surname><given-names>SS</given-names></name><name><surname>Junge</surname><given-names>HJ</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy</article-title><source>EMBO Molecular Medicine</source><volume>13</volume><elocation-id>e13977</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202113977</pub-id><pub-id pub-id-type="pmid">34105895</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Reck and Gpr124 are essential receptor cofactors for Wnt7a/Wnt7b-specific signaling in mammalian CNS angiogenesis and blood-brain barrier regulation</article-title><source>Neuron</source><volume>95</volume><fpage>1056</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.031</pub-id><pub-id pub-id-type="pmid">28803732</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular determinants in Frizzled, Reck, and Wnt7a for ligand-specific signaling in neurovascular development</article-title><source>eLife</source><volume>8</volume><elocation-id>e47300</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.47300</pub-id><pub-id pub-id-type="pmid">31225798</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouinard</surname><given-names>L</given-names></name><name><surname>Felx</surname><given-names>M</given-names></name><name><surname>Mellal</surname><given-names>N</given-names></name><name><surname>Varela</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>P</given-names></name><name><surname>Jolette</surname><given-names>J</given-names></name><name><surname>Samadfam</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>SY</given-names></name><name><surname>Locher</surname><given-names>K</given-names></name><name><surname>Buntich</surname><given-names>S</given-names></name><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Pyrah</surname><given-names>I</given-names></name><name><surname>Boyce</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in A rat lifetime pharmacology study</article-title><source>Regulatory Toxicology and Pharmacology</source><volume>81</volume><fpage>212</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2016.08.010</pub-id><pub-id pub-id-type="pmid">27569204</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cliffe</surname><given-names>A</given-names></name><name><surname>Hamada</surname><given-names>F</given-names></name><name><surname>Bienz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling</article-title><source>Current Biology</source><volume>13</volume><fpage>960</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(03)00370-1</pub-id><pub-id pub-id-type="pmid">12781135</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruciat</surname><given-names>CM</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Secreted and transmembrane wnt inhibitors and activators</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a015081</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a015081</pub-id><pub-id pub-id-type="pmid">23085770</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>A</given-names></name><name><surname>Boxer</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural insight into the photochemistry of split green fluorescent proteins: a unique role for a his-tag</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b10680</pub-id><pub-id pub-id-type="pmid">29193968</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>JR</given-names></name><name><surname>Becerra</surname><given-names>C</given-names></name><name><surname>Richards</surname><given-names>D</given-names></name><name><surname>Mita</surname><given-names>A</given-names></name><name><surname>Osborne</surname><given-names>C</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Henner</surname><given-names>R</given-names></name><name><surname>Kapoun</surname><given-names>AM</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Stagg</surname><given-names>B</given-names></name><name><surname>Uttamsingh</surname><given-names>S</given-names></name><name><surname>Brachmann</surname><given-names>RK</given-names></name><name><surname>Farooki</surname><given-names>A</given-names></name><name><surname>Mita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer</article-title><source>Breast Cancer Research and Treatment</source><volume>184</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05817-w</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dijksterhuis</surname><given-names>JP</given-names></name><name><surname>Baljinnyam</surname><given-names>B</given-names></name><name><surname>Stanger</surname><given-names>K</given-names></name><name><surname>Sercan</surname><given-names>HO</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Andres</surname><given-names>O</given-names></name><name><surname>Rubin</surname><given-names>JS</given-names></name><name><surname>Hannoush</surname><given-names>RN</given-names></name><name><surname>Schulte</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>6789</fpage><lpage>6798</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.612648</pub-id><pub-id pub-id-type="pmid">25605717</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Vlahos</surname><given-names>L</given-names></name><name><surname>Yuki</surname><given-names>K</given-names></name><name><surname>Rada</surname><given-names>CC</given-names></name><name><surname>van Unen</surname><given-names>V</given-names></name><name><surname>Vuppalapaty</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sura</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>AK</given-names></name><name><surname>Tomaske</surname><given-names>M</given-names></name><name><surname>Alwahabi</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Nowatzke</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Yeh</surname><given-names>W-C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Therapeutic blood-brain barrier modulation and stroke treatment by a bioengineered FZD4-selective WNT surrogate in mice</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>2947</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-37689-1</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastman</surname><given-names>P</given-names></name><name><surname>Swails</surname><given-names>J</given-names></name><name><surname>Chodera</surname><given-names>JD</given-names></name><name><surname>McGibbon</surname><given-names>RT</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Beauchamp</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Simmonett</surname><given-names>AC</given-names></name><name><surname>Harrigan</surname><given-names>MP</given-names></name><name><surname>Stern</surname><given-names>CD</given-names></name><name><surname>Wiewiora</surname><given-names>RP</given-names></name><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Pande</surname><given-names>VS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>OpenMM 7: Rapid development of high performance algorithms for molecular dynamics</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005659</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005659</pub-id><pub-id pub-id-type="pmid">28746339</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Mazouni</surname><given-names>D</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cryo-EM structures of peripherin-2 and ROM1 suggest multiple roles in photoreceptor membrane morphogenesis</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eadd3677</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.add3677</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eubelen</surname><given-names>M</given-names></name><name><surname>Bostaille</surname><given-names>N</given-names></name><name><surname>Cabochette</surname><given-names>P</given-names></name><name><surname>Gauquier</surname><given-names>A</given-names></name><name><surname>Tebabi</surname><given-names>P</given-names></name><name><surname>Dumitru</surname><given-names>AC</given-names></name><name><surname>Koehler</surname><given-names>M</given-names></name><name><surname>Gut</surname><given-names>P</given-names></name><name><surname>Alsteens</surname><given-names>D</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Garcia-Pino</surname><given-names>A</given-names></name><name><surname>Vanhollebeke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A molecular mechanism for Wnt ligand-specific signaling</article-title><source>Science</source><volume>361</volume><elocation-id>eaat1178</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat1178</pub-id><pub-id pub-id-type="pmid">30026314</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>O’Neill</surname><given-names>M</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Antropova</surname><given-names>N</given-names></name><name><surname>Senior</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Blackwell</surname><given-names>S</given-names></name><name><surname>Yim</surname><given-names>J</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Protein complex prediction with alphafold-multimer</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.10.04.463034</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>UCSF ChimeraX: Meeting modern challenges in visualization and analysis</article-title><source>Protein Science</source><volume>27</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/pro.3235</pub-id><pub-id pub-id-type="pmid">28710774</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healey</surname><given-names>EG</given-names></name><name><surname>Bishop</surname><given-names>B</given-names></name><name><surname>Elegheert</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>CH</given-names></name><name><surname>Padilla-Parra</surname><given-names>S</given-names></name><name><surname>Siebold</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3016</pub-id><pub-id pub-id-type="pmid">25938661</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinck</surname><given-names>AP</given-names></name><name><surname>Mueller</surname><given-names>TD</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structural biology and evolution of the TGF-β family</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a022103</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a022103</pub-id><pub-id pub-id-type="pmid">27638177</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>FL</given-names></name><name><surname>Chang</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibody display of cell surface receptor tetraspanin12 and SARS-CoV-2 spike protein</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.29.446300</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janda</surname><given-names>CY</given-names></name><name><surname>Dang</surname><given-names>LT</given-names></name><name><surname>You</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>ZA</given-names></name><name><surname>Yan</surname><given-names>KS</given-names></name><name><surname>Marecic</surname><given-names>O</given-names></name><name><surname>Siepe</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Moody</surname><given-names>JD</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling</article-title><source>Nature</source><volume>545</volume><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1038/nature22306</pub-id><pub-id pub-id-type="pmid">28467818</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Ventruto</surname><given-names>V</given-names></name><name><surname>Trese</surname><given-names>MT</given-names></name><name><surname>Shastry</surname><given-names>BS</given-names></name><name><surname>Hejtmancik</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5</article-title><source>American Journal of Human Genetics</source><volume>75</volume><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1086/425080</pub-id><pub-id pub-id-type="pmid">15346351</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junge</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Burton</surname><given-names>JB</given-names></name><name><surname>Paes</surname><given-names>K</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>French</surname><given-names>DM</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>DS</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling</article-title><source>Cell</source><volume>139</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.07.048</pub-id><pub-id pub-id-type="pmid">19837033</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>J</given-names></name><name><surname>Harikumar</surname><given-names>KG</given-names></name><name><surname>Erice</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Melcher</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>LJ</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>2305</fpage><lpage>2319</lpage><pub-id pub-id-type="doi">10.1101/gad.228544.113</pub-id><pub-id pub-id-type="pmid">24186977</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knoblich</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>HX</given-names></name><name><surname>Sharma</surname><given-names>C</given-names></name><name><surname>Fletcher</surname><given-names>AL</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Hemler</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits β-catenin degradation</article-title><source>Cellular and Molecular Life Sciences</source><volume>71</volume><fpage>1305</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1444-8</pub-id><pub-id pub-id-type="pmid">23955570</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubala</surname><given-names>MH</given-names></name><name><surname>Kovtun</surname><given-names>O</given-names></name><name><surname>Alexandrov</surname><given-names>K</given-names></name><name><surname>Collins</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural and thermodynamic analysis of the GFP:GFP-nanobody complex</article-title><source>Protein Science</source><volume>19</volume><fpage>2389</fpage><lpage>2401</lpage><pub-id pub-id-type="doi">10.1002/pro.519</pub-id><pub-id pub-id-type="pmid">20945358</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>MB</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>V</given-names></name><name><surname>Khandan</surname><given-names>L</given-names></name><name><surname>McVey</surname><given-names>J</given-names></name><name><surname>Klymkowsky</surname><given-names>MW</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Junge</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TSPAN12 is a norrin co-receptor that amplifies frizzled4 ligand selectivity and signaling</article-title><source>Cell Reports</source><volume>19</volume><fpage>2809</fpage><lpage>2822</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.004</pub-id><pub-id pub-id-type="pmid">28658627</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapalombella</surname><given-names>R</given-names></name><name><surname>Yeh</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ramanunni</surname><given-names>A</given-names></name><name><surname>Rafiq</surname><given-names>S</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Staubli</surname><given-names>J</given-names></name><name><surname>Lucas</surname><given-names>DM</given-names></name><name><surname>Mani</surname><given-names>R</given-names></name><name><surname>Herman</surname><given-names>SEM</given-names></name><name><surname>Johnson</surname><given-names>AJ</given-names></name><name><surname>Lozanski</surname><given-names>A</given-names></name><name><surname>Andritsos</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Flynn</surname><given-names>JM</given-names></name><name><surname>Lannutti</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Algate</surname><given-names>P</given-names></name><name><surname>Stromatt</surname><given-names>S</given-names></name><name><surname>Jarjoura</surname><given-names>D</given-names></name><name><surname>Mo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Lozanski</surname><given-names>G</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><name><surname>Tridandapani</surname><given-names>S</given-names></name><name><surname>Freitas</surname><given-names>MA</given-names></name><name><surname>Muthusamy</surname><given-names>N</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals</article-title><source>Cancer Cell</source><volume>21</volume><fpage>694</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.03.040</pub-id><pub-id pub-id-type="pmid">22624718</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Baxa</surname><given-names>U</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A frizzled‐like cysteine‐rich domain in glypican‐3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice</article-title><source>Hepatology</source><volume>70</volume><fpage>1231</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1002/hep.30646</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipper</surname><given-names>CH</given-names></name><name><surname>Egan</surname><given-names>ED</given-names></name><name><surname>Gabriel</surname><given-names>KH</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structural basis for membrane-proximal proteolysis of substrates by ADAM10</article-title><source>Cell</source><volume>186</volume><fpage>3632</fpage><lpage>3641</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.06.026</pub-id><pub-id pub-id-type="pmid">37516108</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Casillas</surname><given-names>F</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Betaglycan presents ligand to the TGF beta signaling receptor</article-title><source>Cell</source><volume>73</volume><fpage>1435</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90368-z</pub-id><pub-id pub-id-type="pmid">8391934</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Steinhart</surname><given-names>Z</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-molecule dynamics of Dishevelled at the plasma membrane and Wnt pathway activation</article-title><source>PNAS</source><volume>117</volume><fpage>16690</fpage><lpage>16701</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910547117</pub-id><pub-id pub-id-type="pmid">32601235</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>JP</given-names></name><name><surname>Bruguera</surname><given-names>ES</given-names></name><name><surname>Vasishtha</surname><given-names>M</given-names></name><name><surname>Killingsworth</surname><given-names>LB</given-names></name><name><surname>Kyaw</surname><given-names>S</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PI(4,5)P<sub>2</sub>-stimulated positive feedback drives the recruitment of Dishevelled to Frizzled in Wnt-β-catenin signaling</article-title><source>Science Signaling</source><volume>15</volume><elocation-id>eabo2820</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.abo2820</pub-id><pub-id pub-id-type="pmid">35998232</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattila</surname><given-names>PK</given-names></name><name><surname>Feest</surname><given-names>C</given-names></name><name><surname>Depoil</surname><given-names>D</given-names></name><name><surname>Treanor</surname><given-names>B</given-names></name><name><surname>Montaner</surname><given-names>B</given-names></name><name><surname>Otipoby</surname><given-names>KL</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Justement</surname><given-names>LB</given-names></name><name><surname>Bruckbauer</surname><given-names>A</given-names></name><name><surname>Batista</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling</article-title><source>Immunity</source><volume>38</volume><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.019</pub-id><pub-id pub-id-type="pmid">23499492</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>Schütze</surname><given-names>K</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ColabFold: making protein folding accessible to all</article-title><source>Nature Methods</source><volume>19</volume><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id><pub-id pub-id-type="pmid">35637307</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Armit</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><name><surname>Venkataraman</surname><given-names>S</given-names></name><name><surname>Frankel</surname><given-names>P</given-names></name><name><surname>Baldock</surname><given-names>RA</given-names></name><name><surname>Davidson</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Integrated analysis of Wnt signalling system component gene expression</article-title><source>Development</source><volume>149</volume><elocation-id>dev200312</elocation-id><pub-id pub-id-type="doi">10.1242/dev.200312</pub-id><pub-id pub-id-type="pmid">35831952</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Whisler</surname><given-names>E</given-names></name><name><surname>Logas</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sampathkumar</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Suen</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yeh</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SZN-413, a monospecific Fzd4 agonist as a potential novel therapeutic for the treatment of diabetic retinopathy</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>63</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1167/tvst.11.9.19</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikopoulos</surname><given-names>K</given-names></name><name><surname>Venselaar</surname><given-names>H</given-names></name><name><surname>Collin</surname><given-names>RWJ</given-names></name><name><surname>Riveiro-Alvarez</surname><given-names>R</given-names></name><name><surname>Boonstra</surname><given-names>FN</given-names></name><name><surname>Hooymans</surname><given-names>JMM</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Shears</surname><given-names>D</given-names></name><name><surname>van Bers</surname><given-names>M</given-names></name><name><surname>de Wijs</surname><given-names>IJ</given-names></name><name><surname>van Essen</surname><given-names>AJ</given-names></name><name><surname>Sijmons</surname><given-names>RH</given-names></name><name><surname>Tilanus</surname><given-names>MAD</given-names></name><name><surname>van Nouhuys</surname><given-names>CE</given-names></name><name><surname>Ayuso</surname><given-names>C</given-names></name><name><surname>Hoefsloot</surname><given-names>LH</given-names></name><name><surname>Cremers</surname><given-names>FPM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP</article-title><source>Human Mutation</source><volume>31</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1002/humu.21250</pub-id><pub-id pub-id-type="pmid">20340138</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Wnt genes</article-title><source>Cell</source><volume>69</volume><fpage>1073</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90630-u</pub-id><pub-id pub-id-type="pmid">1617723</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt/β-catenin signaling, disease, and emerging therapeutic modalities</article-title><source>Cell</source><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Brien</surname><given-names>S</given-names></name><name><surname>Chidiac</surname><given-names>R</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Modulation of Wnt-β-catenin signaling with antibodies: therapeutic opportunities and challenges</article-title><source>Trends in Pharmacological Sciences</source><volume>44</volume><fpage>354</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2023.03.008</pub-id><pub-id pub-id-type="pmid">37085400</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otomo</surname><given-names>R</given-names></name><name><surname>Otsubo</surname><given-names>C</given-names></name><name><surname>Matsushima-Hibiya</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Tashiro</surname><given-names>F</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Ochiya</surname><given-names>T</given-names></name><name><surname>Yokota</surname><given-names>J</given-names></name><name><surname>Nakagama</surname><given-names>H</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Enari</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion</article-title><source>PNAS</source><volume>111</volume><fpage>18691</fpage><lpage>18696</lpage><pub-id pub-id-type="doi">10.1073/pnas.1412062112</pub-id><pub-id pub-id-type="pmid">25512506</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Volpicelli-Daley</surname><given-names>L</given-names></name><name><surname>Swan</surname><given-names>L</given-names></name><name><surname>Lucast</surname><given-names>L</given-names></name><name><surname>Khoo</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Abrams</surname><given-names>CS</given-names></name><name><surname>Sokol</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation</article-title><source>Science</source><volume>321</volume><fpage>1350</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1126/science.1160741</pub-id><pub-id pub-id-type="pmid">18772438</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagiotou</surname><given-names>ES</given-names></name><name><surname>Sanjurjo Soriano</surname><given-names>C</given-names></name><name><surname>Poulter</surname><given-names>JA</given-names></name><name><surname>Lord</surname><given-names>EC</given-names></name><name><surname>Dzulova</surname><given-names>D</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Hiyoshi</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>BHY</given-names></name><name><surname>Chu</surname><given-names>YWY</given-names></name><name><surname>Lai</surname><given-names>CHY</given-names></name><name><surname>Tafoya</surname><given-names>ME</given-names></name><name><surname>Karjosukarso</surname><given-names>D</given-names></name><name><surname>Collin</surname><given-names>RWJ</given-names></name><name><surname>Topping</surname><given-names>J</given-names></name><name><surname>Downey</surname><given-names>LM</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Inglehearn</surname><given-names>CF</given-names></name><name><surname>Toomes</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defects in the cell signaling mediator β-catenin cause the retinal vascular condition FEVR</article-title><source>American Journal of Human Genetics</source><volume>100</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.05.001</pub-id><pub-id pub-id-type="pmid">28575650</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Laeremans</surname><given-names>T</given-names></name><name><surname>Triest</surname><given-names>S</given-names></name><name><surname>Rasmussen</surname><given-names>SGF</given-names></name><name><surname>Wohlkönig</surname><given-names>A</given-names></name><name><surname>Ruf</surname><given-names>A</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Hol</surname><given-names>WGJ</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A general protocol for the generation of Nanobodies for structural biology</article-title><source>Nature Protocols</source><volume>9</volume><fpage>674</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.039</pub-id><pub-id pub-id-type="pmid">24577359</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phoenix</surname><given-names>TN</given-names></name><name><surname>Patmore</surname><given-names>DM</given-names></name><name><surname>Boop</surname><given-names>S</given-names></name><name><surname>Boulos</surname><given-names>N</given-names></name><name><surname>Jacus</surname><given-names>MO</given-names></name><name><surname>Patel</surname><given-names>YT</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Goumnerova</surname><given-names>L</given-names></name><name><surname>Perreault</surname><given-names>S</given-names></name><name><surname>Wadhwa</surname><given-names>E</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Stewart</surname><given-names>CF</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Medulloblastoma genotype dictates blood brain barrier phenotype</article-title><source>Cancer Cell</source><volume>29</volume><fpage>508</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.03.002</pub-id><pub-id pub-id-type="pmid">27050100</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Yum</surname><given-names>S</given-names></name><name><surname>Stamos</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>JK</given-names></name><name><surname>Park</surname><given-names>BJ</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Ha</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e4046</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004046</pub-id><pub-id pub-id-type="pmid">19107203</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulter</surname><given-names>JA</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Gilmour</surname><given-names>DF</given-names></name><name><surname>Rice</surname><given-names>A</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Kearns</surname><given-names>LS</given-names></name><name><surname>Ruddle</surname><given-names>JB</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Pierce</surname><given-names>EA</given-names></name><name><surname>Downey</surname><given-names>LM</given-names></name><name><surname>Mohamed</surname><given-names>MD</given-names></name><name><surname>Markham</surname><given-names>AF</given-names></name><name><surname>Inglehearn</surname><given-names>CF</given-names></name><name><surname>Toomes</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy</article-title><source>American Journal of Human Genetics</source><volume>86</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2010.01.012</pub-id><pub-id pub-id-type="pmid">20159112</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawal</surname><given-names>N</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name><name><surname>Sousa</surname><given-names>KM</given-names></name><name><surname>Kele</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Okano</surname><given-names>H</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dynamic temporal and cell type-specific expression of Wnt signaling components in the developing midbrain</article-title><source>Experimental Cell Research</source><volume>312</volume><fpage>1626</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2006.01.032</pub-id><pub-id pub-id-type="pmid">16510140</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichsman</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Cumberledge</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction</article-title><source>The Journal of Cell Biology</source><volume>135</volume><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1083/jcb.135.3.819</pub-id><pub-id pub-id-type="pmid">8909553</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rim</surname><given-names>EY</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The wnt pathway: from signaling mechanisms to synthetic modulators</article-title><source>Annual Review of Biochemistry</source><volume>91</volume><fpage>571</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-040320-103615</pub-id><pub-id pub-id-type="pmid">35303793</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>TK</given-names></name><name><surname>Grinkova</surname><given-names>YV</given-names></name><name><surname>Bayburt</surname><given-names>TH</given-names></name><name><surname>Denisov</surname><given-names>IG</given-names></name><name><surname>Zolnerciks</surname><given-names>JK</given-names></name><name><surname>Atkins</surname><given-names>WM</given-names></name><name><surname>Sligar</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs</article-title><source>Methods in Enzymology</source><volume>464</volume><fpage>211</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(09)64011-8</pub-id><pub-id pub-id-type="pmid">19903557</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robitaille</surname><given-names>J</given-names></name><name><surname>MacDonald</surname><given-names>MLE</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name><name><surname>Sheldahl</surname><given-names>LC</given-names></name><name><surname>Zeisler</surname><given-names>J</given-names></name><name><surname>Dubé</surname><given-names>MP</given-names></name><name><surname>Zhang</surname><given-names>LH</given-names></name><name><surname>Singaraja</surname><given-names>RR</given-names></name><name><surname>Guernsey</surname><given-names>DL</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Siebert</surname><given-names>LF</given-names></name><name><surname>Hoskin-Mott</surname><given-names>A</given-names></name><name><surname>Trese</surname><given-names>MT</given-names></name><name><surname>Pimstone</surname><given-names>SN</given-names></name><name><surname>Shastry</surname><given-names>BS</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Goldberg</surname><given-names>YP</given-names></name><name><surname>Samuels</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy</article-title><source>Nature Genetics</source><volume>32</volume><fpage>326</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/ng957</pub-id><pub-id pub-id-type="pmid">12172548</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Frizzleds and WNT/β-catenin signaling--The black box of ligand-receptor selectivity, complex stoichiometry and activation kinetics</article-title><source>European Journal of Pharmacology</source><volume>763</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.05.031</pub-id><pub-id pub-id-type="pmid">26003275</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz-Romond</surname><given-names>T</given-names></name><name><surname>Metcalfe</surname><given-names>C</given-names></name><name><surname>Bienz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dynamic recruitment of axin by Dishevelled protein assemblies</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>2402</fpage><lpage>2412</lpage><pub-id pub-id-type="doi">10.1242/jcs.002956</pub-id><pub-id pub-id-type="pmid">17606995</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shastry</surname><given-names>BS</given-names></name><name><surname>Pendergast</surname><given-names>SD</given-names></name><name><surname>Hartzer</surname><given-names>MK</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Trese</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity</article-title><source>Archives of Ophthalmology</source><volume>115</volume><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1001/archopht.1997.01100150653015</pub-id><pub-id pub-id-type="pmid">9152134</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Ke</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Melcher</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural basis of the Norrin-Frizzled 4 interaction</article-title><source>Cell Research</source><volume>25</volume><fpage>1078</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.92</pub-id><pub-id pub-id-type="pmid">26227961</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Leahy</surname><given-names>DJ</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mutational analysis of Norrin-Frizzled4 recognition</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>4057</fpage><lpage>4068</lpage><pub-id pub-id-type="doi">10.1074/jbc.M609618200</pub-id><pub-id pub-id-type="pmid">17158104</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soker</surname><given-names>S</given-names></name><name><surname>Miao</surname><given-names>HQ</given-names></name><name><surname>Nomi</surname><given-names>M</given-names></name><name><surname>Takashima</surname><given-names>S</given-names></name><name><surname>Klagsbrun</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding</article-title><source>Journal of Cellular Biochemistry</source><volume>85</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1002/jcb.10140</pub-id><pub-id pub-id-type="pmid">11948691</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamos</surname><given-names>JL</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Regard</surname><given-names>JB</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Bart</surname><given-names>O</given-names></name><name><surname>Cadigan</surname><given-names>KM</given-names></name><name><surname>Waterman</surname><given-names>ML</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Saja</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>BM</given-names></name><name><surname>Eisenmann</surname><given-names>DM</given-names></name><name><surname>Holstein</surname><given-names>TW</given-names></name><name><surname>Chien</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The β-catenin destruction complex</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a007898</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a007898</pub-id><pub-id pub-id-type="pmid">23169527</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>MG</given-names></name><name><surname>Brown</surname><given-names>AI</given-names></name><name><surname>Vega-Lugo</surname><given-names>J</given-names></name><name><surname>Borges</surname><given-names>JP</given-names></name><name><surname>Scott</surname><given-names>AM</given-names></name><name><surname>Jaqaman</surname><given-names>K</given-names></name><name><surname>Fairn</surname><given-names>GD</given-names></name><name><surname>Antonescu</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>2681</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-38390-z</pub-id><pub-id pub-id-type="pmid">37160944</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summerhurst</surname><given-names>K</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Sharpe</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>3D representation of Wnt and Frizzled gene expression patterns in the mouse embryo at embryonic day 11.5 (Ts19)</article-title><source>Gene Expression Patterns</source><volume>8</volume><fpage>331</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.gep.2008.01.007</pub-id><pub-id pub-id-type="pmid">18364260</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susa</surname><given-names>KJ</given-names></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81</article-title><source>Science</source><volume>371</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1126/science.abd9836</pub-id><pub-id pub-id-type="pmid">33446559</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susa</surname><given-names>KJ</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Tetraspanins: structure, dynamics, and principles of partner-protein recognition</article-title><source>Trends in Cell Biology</source><volume>34</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2023.09.003</pub-id><pub-id pub-id-type="pmid">37783654</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Garralda</surname><given-names>E</given-names></name><name><surname>Tai</surname><given-names>D</given-names></name><name><surname>De Braud</surname><given-names>F</given-names></name><name><surname>Geva</surname><given-names>R</given-names></name><name><surname>van Bussel</surname><given-names>MTJ</given-names></name><name><surname>Fiorella Dotti</surname><given-names>K</given-names></name><name><surname>Elez</surname><given-names>E</given-names></name><name><surname>de Miguel</surname><given-names>MJ</given-names></name><name><surname>Litwiler</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A phase Ib/II study of WNT974 + encorafenib + cetuximab in patients with BRAF V600E-mutant KRAS wild-type metastatic colorectal cancer</article-title><source>The Oncologist</source><volume>28</volume><fpage>230</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad007</pub-id><pub-id pub-id-type="pmid">36811382</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauriello</surname><given-names>DVF</given-names></name><name><surname>Jordens</surname><given-names>I</given-names></name><name><surname>Kirchner</surname><given-names>K</given-names></name><name><surname>Slootstra</surname><given-names>JW</given-names></name><name><surname>Kruitwagen</surname><given-names>T</given-names></name><name><surname>Bouwman</surname><given-names>BAM</given-names></name><name><surname>Noutsou</surname><given-names>M</given-names></name><name><surname>Rüdiger</surname><given-names>SGD</given-names></name><name><surname>Schwamborn</surname><given-names>K</given-names></name><name><surname>Schambony</surname><given-names>A</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt/β-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled</article-title><source>PNAS</source><volume>109</volume><fpage>E812</fpage><lpage>E820</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114802109</pub-id><pub-id pub-id-type="pmid">22411803</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Liebschner</surname><given-names>D</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Poon</surname><given-names>BK</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Oeffner</surname><given-names>RD</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>AlphaFold predictions are valuable hypotheses and accelerate but do not replace experimental structure determination</article-title><source>Nature Methods</source><volume>21</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/s41592-023-02087-4</pub-id><pub-id pub-id-type="pmid">38036854</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toomes</surname><given-names>C</given-names></name><name><surname>Bottomley</surname><given-names>HM</given-names></name><name><surname>Jackson</surname><given-names>RM</given-names></name><name><surname>Towns</surname><given-names>KV</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Trembath</surname><given-names>R</given-names></name><name><surname>Woodruff</surname><given-names>G</given-names></name><name><surname>Gregory-Evans</surname><given-names>CY</given-names></name><name><surname>Gregory-Evans</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>MJ</given-names></name><name><surname>Black</surname><given-names>GCM</given-names></name><name><surname>Downey</surname><given-names>LM</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Inglehearn</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q</article-title><source>American Journal of Human Genetics</source><volume>74</volume><fpage>721</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1086/383202</pub-id><pub-id pub-id-type="pmid">15024691</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsumi</surname><given-names>N</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Waghray</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>Caveney</surname><given-names>NA</given-names></name><name><surname>Janda</surname><given-names>CY</given-names></name><name><surname>Hannoush</surname><given-names>RN</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structure of the Wnt-Frizzled-LRP6 initiation complex reveals the basis for coreceptor discrimination</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2218238120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2218238120</pub-id><pub-id pub-id-type="pmid">36893265</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeda</surname><given-names>R</given-names></name><name><surname>Satouh</surname><given-names>Y</given-names></name><name><surname>Takemoto</surname><given-names>M</given-names></name><name><surname>Nakada-Nakura</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>T</given-names></name><name><surname>Shirouzu</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Ikawa</surname><given-names>M</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural insights into tetraspanin CD9 function</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1606</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15459-7</pub-id><pub-id pub-id-type="pmid">32231207</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallon</surname><given-names>M</given-names></name><name><surname>Yuki</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Siepe</surname><given-names>D</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Essler</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A RECK-WNT7 receptor-ligand interaction enables isoform-specific regulation of wnt bioavailability</article-title><source>Cell Reports</source><volume>25</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.045</pub-id><pub-id pub-id-type="pmid">30304675</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Deventer</surname><given-names>SJ</given-names></name><name><surname>Dunlock</surname><given-names>V-ME</given-names></name><name><surname>van Spriel</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular interactions shaping the tetraspanin web</article-title><source>Biochemical Society Transactions</source><volume>45</volume><fpage>741</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1042/BST20160284</pub-id><pub-id pub-id-type="pmid">28620035</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhollebeke</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>OA</given-names></name><name><surname>Bostaille</surname><given-names>N</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Maquet</surname><given-names>E</given-names></name><name><surname>Gauquier</surname><given-names>A</given-names></name><name><surname>Cabochette</surname><given-names>P</given-names></name><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Mochizuki</surname><given-names>N</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tip cell-specific requirement for an atypical Gpr124- and Reck-dependent Wnt/β-catenin pathway during brain angiogenesis</article-title><source>eLife</source><volume>4</volume><elocation-id>e06489</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.06489</pub-id><pub-id pub-id-type="pmid">26051822</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voloshanenko</surname><given-names>O</given-names></name><name><surname>Gmach</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Kranz</surname><given-names>D</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mapping of Wnt-Frizzled interactions by multiplex CRISPR targeting of receptor gene families</article-title><source>FASEB Journal</source><volume>31</volume><fpage>4832</fpage><lpage>4844</lpage><pub-id pub-id-type="doi">10.1096/fj.201700144R</pub-id><pub-id pub-id-type="pmid">28733458</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZX</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule</article-title><source>FEBS Letters</source><volume>360</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(95)00062-e</pub-id><pub-id pub-id-type="pmid">7875313</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rattner</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity</article-title><source>Cell</source><volume>151</volume><fpage>1332</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.10.042</pub-id><pub-id pub-id-type="pmid">23217714</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Junge</surname><given-names>HJ</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interplay of the Norrin and Wnt7a/Wnt7b signaling systems in blood–brain barrier and blood–retina barrier development and maintenance</article-title><source>PNAS</source><volume>115</volume><elocation-id>MC6294914</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.1813217115</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whorton</surname><given-names>MR</given-names></name><name><surname>Bokoch</surname><given-names>MP</given-names></name><name><surname>Rasmussen</surname><given-names>SGF</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Zare</surname><given-names>RN</given-names></name><name><surname>Kobilka</surname><given-names>B</given-names></name><name><surname>Sunahara</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A monomeric G protein-coupled receptor isolated in A high-density lipoprotein particle efficiently activates its G protein</article-title><source>PNAS</source><volume>104</volume><fpage>7682</fpage><lpage>7687</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611448104</pub-id><pub-id pub-id-type="pmid">17452637</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dabdoub</surname><given-names>A</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Woods</surname><given-names>C</given-names></name><name><surname>Kelley</surname><given-names>MW</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Tasman</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair</article-title><source>Cell</source><volume>116</volume><fpage>883</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00216-8</pub-id><pub-id pub-id-type="pmid">15035989</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Oda</surname><given-names>T</given-names></name><name><surname>Kikkawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Unveiling Liquid-Crystalline Lipids in the Urothelial Membrane through Cryo-EM</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.05.29.542358</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>XR</given-names></name><name><surname>Greenberg</surname><given-names>ZJ</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Egawa</surname><given-names>T</given-names></name><name><surname>Gross</surname><given-names>ML</given-names></name><name><surname>Schuettpelz</surname><given-names>LG</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Open conformation of tetraspanins shapes interaction partner networks on cell membranes</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e105246</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020105246</pub-id><pub-id pub-id-type="pmid">32974937</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang-Snyder</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>JR</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Lai</surname><given-names>C-J</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A frizzled homolog functions in A vertebrate Wnt signaling pathway</article-title><source>Current Biology</source><volume>6</volume><fpage>1302</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(02)70716-1</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yauch</surname><given-names>RL</given-names></name><name><surname>Berditchevski</surname><given-names>F</given-names></name><name><surname>Harler</surname><given-names>MB</given-names></name><name><surname>Reichner</surname><given-names>J</given-names></name><name><surname>Hemler</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration</article-title><source>Molecular Biology of the Cell</source><volume>9</volume><fpage>2751</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1091/mbc.9.10.2751</pub-id><pub-id pub-id-type="pmid">9763442</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yauch</surname><given-names>RL</given-names></name><name><surname>Hemler</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase</article-title><source>The Biochemical Journal</source><volume>351 Pt 3</volume><fpage>629</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1042/bj3510629</pub-id><pub-id pub-id-type="pmid">11042117</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cahill</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Badea</surname><given-names>TC</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Peachey</surname><given-names>NS</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization</article-title><source>Cell</source><volume>139</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.07.047</pub-id><pub-id pub-id-type="pmid">19837032</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name><name><surname>Yokota</surname><given-names>C</given-names></name><name><surname>Almeida</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Doble</surname><given-names>B</given-names></name><name><surname>Woodgett</surname><given-names>J</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions</article-title><source>Development</source><volume>135</volume><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1242/dev.013540</pub-id><pub-id pub-id-type="pmid">18077588</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XA</given-names></name><name><surname>Bontrager</surname><given-names>AL</given-names></name><name><surname>Hemler</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>25005</fpage><lpage>25013</lpage><pub-id pub-id-type="doi">10.1074/jbc.M102156200</pub-id><pub-id pub-id-type="pmid">11325968</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lai</surname><given-names>MB</given-names></name><name><surname>Khandan</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>LA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Junge</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Norrin-induced Frizzled4 endocytosis and endo-lysosomal trafficking control retinal angiogenesis and barrier function</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>16050</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms16050</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical wnt signaling</article-title><source>Developmental Cell</source><volume>31</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.08.018</pub-id><pub-id pub-id-type="pmid">25373781</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>B</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>McMillan</surname><given-names>BJ</given-names></name><name><surname>Seegar</surname><given-names>TCM</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket</article-title><source>Cell</source><volume>167</volume><fpage>1041</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.056</pub-id><pub-id pub-id-type="pmid">27881302</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuidscherwoude</surname><given-names>M</given-names></name><name><surname>Göttfert</surname><given-names>F</given-names></name><name><surname>Dunlock</surname><given-names>VME</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>van den Bogaart</surname><given-names>G</given-names></name><name><surname>van Spriel</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The tetraspanin web revisited by super-resolution microscopy</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>12201</elocation-id><pub-id pub-id-type="doi">10.1038/srep12201</pub-id><pub-id pub-id-type="pmid">26183063</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96743.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Araç</surname><given-names>Demet</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Chicago</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This is a <bold>fundamental</bold> study that addresses the key question of how the tetraspanin Tspan12 functions biochemically as a co-receptor for Norrin to initiate β-catenin signaling. The strength of the work lies in the rigorous and <bold>compelling</bold> binding analyses involving various purified receptors, co-receptors, and ligands, as well as molecular modeling by AlphaFold that was subsequently validated by an extensive series of mutagenesis experiments. The study advances the field by providing a novel mechanism of co-receptor function and shedding new light on how signaling specificity is achieved in the complex Wnt/Norrin signaling system.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96743.3.sa1</article-id><title-group><article-title>Joint Public Review:</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Though the Norrin protein is structurally unrelated to the Wnt ligands, it can activate the Wnt/β-catenin pathway by binding to the canonical Wnt receptors Fzd4 and Lrp5/6, as well as the tetraspanin Tspan12 co-receptor. Understanding the biochemical mechanisms by which Norrin engages Tspan12 to initiate signaling is important, as this pathway plays an important role in regulating retinal angiogenesis and maintaining the blood-retina-barrier. Numerous mutations in this signaling pathway have also been found in human patients with ocular diseases. The overarching goal of the study is to define the biochemical mechanisms by which Tspan12 mediates Norrin signaling. Using purified Tspan12 reconstituted in lipid nanodiscs, the authors conducted detailed binding experiments to document the direct, high-affinity interactions between purified Tspan12 and Norrin. To further model this binding event, they used AlphaFold to dock Norrin and Tspan12 and identified four putative binding sites. They went on to validate these sites through mutagenesis experiments. Using the information obtained from the AlphaFold modeling and through additional binding competition experiments, it was further demonstrated that Tspan12 and Fzd4 can bind Norrin simultaneously, but Tspan12 binding to Norrin is competitive with other known co-receptors, such as HSPGs and Lrp5/6. Collectively, the authors proposed that the main function of Tspan12 is to capture low concentrations of Norrin at the early stage of signaling, and then &quot;hand over&quot; Norrin to Fzd4 and Lrp5/6 for further signal propagation. Overall, the study is comprehensive and compelling, and the conclusions are well supported by the experimental and modeling data.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96743.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bruguera</surname><given-names>Elise S</given-names></name><role specific-use="author">Author</role><aff><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Mahoney</surname><given-names>Jacob P</given-names></name><role specific-use="author">Author</role><aff><institution>Stanford University School of Medicine</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Weis</surname><given-names>William I</given-names></name><role specific-use="author">Author</role><aff><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Though the Norrin protein is structurally unrelated to the Wnt ligands, it can activate the Wnt/βcatenin pathway by binding to the canonical Wnt receptors Fzd4 and Lrp5/6, as well as the tetraspanin Tspan12 co-receptor. Understanding the biochemical mechanisms by which Norrin engages Tspan12 to initiate signaling is important, as this pathway plays an important role in regulating retinal angiogenesis and maintaining the blood-retina-barrier. Numerous mutations in this signaling pathway have also been found in human patients with ocular diseases. The overarching goal of the study is to define the biochemical mechanisms by which Tspan12 mediates Norrin signaling. Using purified Tspan12 reconstituted in lipid nanodiscs, the authors conducted detailed binding experiments to document the direct, high-affinity interactions between purified Tspan12 and Norrin. To further model this binding event, they used AlphaFold to dock Norrin and Tspan12 and identified four putative binding sites. They went on to validate these sites through mutagenesis experiments. Using the information obtained from the AlphaFold modeling and through additional binding competition experiments, it was further demonstrated that Tspan12 and Fzd4 can bind Norrin simultaneously, but Tspan12 binding to Norrin is competitive with other known co-receptors, such as HSPGs and Lrp5/6. Collectively, the authors proposed that the main function of Tspan12 is to capture low concentrations of Norrin at the early stage of signaling, and then &quot;hand over&quot; Norrin to Fzd4 and Lrp5/6 for further signal propagation. Overall, the study is comprehensive and compelling, and the conclusions are well supported by the experimental and modeling data.</p><p>Strengths:</p><p>• Biochemical reconstitution of Tspan12 and Fzd4 in lipid nanodiscs is an elegant approach for testing the direct binding interaction between Norrin and its co-receptors. The proteins used for the study seem to be of high purity and quality.</p><p>• The various binding experiments presented throughout the study were carried out rigorously. In particular, BLI allows accurate measurement of equilibrium binding constants as well as on and off rates.</p><p>• It is nice to see that the authors followed up on their AlphaFold modeling with an extensive series of mutagenesis studies to experimentally validate the potential binding sites. This adds credence to the AlphaFold models.</p><p>• Table S1 is a further testament to the rigor of the study.</p><p>• Overall, the study is comprehensive and compelling, and the conclusions are well supported by the experimental and modeling data.</p><p>Suggestions for improvement:</p><p>• It would be helpful to show Coomassie-stained gels of the key mutant Norrin and Tspan12 proteins presented in Figures 2E and 2F.</p></disp-quote><p>We have included Stain-Free SDS-PAGE gels from the purification of the Norrin and Tspan12 mutants in a new Figure S4.</p><disp-quote content-type="editor-comment"><p>• Many Norrin and Tspan12 mutations have been identified in human patients with FEVR. It would be interesting to comment on whether any of the mutations might affect the NorrinTspan12 binding sites described in this study.</p></disp-quote><p>Thank you for this suggestion. We have inspected human mutation databases gnomAD, ClinVar, and HGMD for known mutations in the predicted Tspan12-Norrin binding interface and their occurrence in human patients with FEVR or Norrie disease.</p><p>While a number of Tspan12 residues that we predict to interact with Norrin are impacted by rare mutations in humans (e.g., L169M, E170V, E173K, D175N, E196G, S199C, as found in the gnomAD database), these alleles are of unknown clinical significance (as found in ClinVar or HGMD databases). It is possible that mutations that slightly weaken the Norrin-Tspan12 interface may not produce a strong phenotype, especially given the avidity we expect from this system. By our examination, the missense variants of clinical significance that have been found in the Tspan12 LEL would be expected to destabilize the protein (i.e., mutations to or from cysteine or proline, or mutations to residues involved in packing interactions within the LEL fold), and therefore these mutations may produce a disease phenotype by impacting Tspan12 protein expression levels.</p><p>Several Norrin mutations that are associated with Norrie disease, FEVR, or other diseases of the retinal vasculature have been found in the predicted Tspan12 binding site. For example, Norrin mutations at positions L103 (L103Q, L103V), K104 (K104N, K104Q), and A105 (A105T, A105P, A105E, A105S, A105T, A105V) have been found in patients, all of which may disrupt binding to Tspan12. However, the deleterious effect of K104 mutations on Norrin-stimulated signaling could also be explained by a weakened Norrin-Fzd4 binding interface. Norrin mutations at R115 (R115L and R115Q), as well as R121 (R121L, R121G, R121Q, and R121W) have also been found in patients with various diseases of the retinal vasculature. Additionally, the Norrin mutation T119P has been found in patients with Norrie disease, but we would expect this mutation to destabilize Norrin in addition to disrupting the Tspan12 binding site.</p><p>While we commented briefly on mutations R115L and R121W in the original draft (page 5, paragraphs 4 and 1, respectively), we have updated the manuscript with more comments on disease-associated mutations to the predicted Tspan12 binding site on Norrin (page 5, first partial paragraph; page 9, first partial paragraph).</p><disp-quote content-type="editor-comment"><p>• Some of the negative conclusions (e.g. the lack of involvement of Tspan12 in the formation of the Norrin-Lrp5/6-Fzd4-Dvl signaling complex) can be difficult to interpret. There are many possible reasons as to why certain biological effects are not recapitulated in a reconstitution experiment. For instance, the recombinant proteins used in the experiment may not be presented in the correct configurations, and certain biochemical modifications, such as phosphorylation, may also be missing.</p></disp-quote><p>We agree that different Tspan12 and Fzd4 stoichiometries, lipid compositions, and posttranslational modifications could impact the results of our study, and that it is important to mention these possibilities. We have added these caveats to the discussion section (page 10, last paragraph).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>This is an interesting study of high quality with important and novel findings. Bruguera et al. report a biochemical and structural analysis of the Tspan12 co-receptor for norrin. Major findings are that Norrin directly binds Tspan12 with high affinity (this is consistent with a report on BioRxiv: Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike protein) and a predicted structure of Tspan12 alone or in complex with Norrin. The</p><p>Norrin/Tspan12 binding interface is largely verified by mutational analysis. An interaction of the Tspan12 large extracellular loop (LEL) with Fzd4 cannot be detected and interactions of fulllength Tspan12 and Fzd4 cannot be tested using nano-disc based BLI, however, Fzd4/Tspan12 heterodimers can be purified and inserted into nanodiscs when aided by split GFP tags. An analysis of a potential composite binding site of a Fzd4/Tspan12 complex is somewhat inconclusive, as no major increase in affinity is detected for the complex compared to the individual components. A caveat to this data is that affinity measurements were performed for complexes with approximately 1 molecule Tspan12 and FZD4 per nanodisc, while the composite binding site could potentially be formed only in higher order complexes, e.g., 2:2 Fzd4/Tspan12 complexes. Interestingly, the authors find that the Norrin/Tspan12 binding site and the Norrin/Lrp6 binding site partially overlap and that the Lrp6 ectodomain competes with Tspan12 for Norrin binding. This result leads the authors to propose a model according to which Tspan12 captures Norrin and then has to &quot;hand it off&quot; to allow for Fzd4/Lrp6 formation. By increasing the local concentration of Norrin, Tspan12 would enhance the formation of the Fzd4/Lrp5 or Fzd4/Lrp6 complex.</p></disp-quote><p>Thank you for pointing out the BioRxiv report showing Norrin-Tspan12 LEL binding. We have cited this in the introduction of our revised manuscript (page 2, paragraph 3).</p><disp-quote content-type="editor-comment"><p>The experiments based on membrane proteins inserted into nano-discs and the structure prediction using AlphaFold yield important new insights into a protein complex that has critical roles in normal CNS vascular biology, retinal vascular disease, and is a target for therapeutic intervention. However, it remains unclear how Norrin would be &quot;handed off&quot; from Tspan12 or Tspan12/Fzd4 complexes to Fzd4/Lrp6 complexes, as the relatively high affinity of Norrin to Fzd4/Tspan12 dimers likely does not favor the &quot;handing off&quot; to Fzd4/Lrp6 complexes.</p></disp-quote><p>While the Fzd4-Tspan12 interaction is strong, our data suggest that Fzd4 and Tspan12 bind Norrin with negative cooperativity, suggesting that Fzd4 binding may enhance Norrin-Tspan12 dissociation to facilitate handoff. This model is based on (1) the dissociation of Norrin from beadbound Tspan12 in the presence of saturating Fzd4 CRD (Figure 3D), and (2) a weaker measured affinity of Norrin-Tspan12LEL in the presence of saturating Fzd4 CRD (Figure 3F). We have now added wording to emphasize this in the discussion section (page 9, end of first full paragraph).</p><p>However, as you note, the Norrin-Tspan12 affinity that we measured in the presence of Fzd CRD (tens of nM) is still much stronger than the known Norrin-LRP6 affinity (0.5-1µM), which predicts that the efficiency of this handoff may be low. We have now commented on this in the discussion section and mentioned an alternative model in which Tspan12 presents the second Norrin protomer to LRP5/6 for signaling, instead of dissociating (page 9, paragraph 2). However, the handoff efficiency could also be impacted by other factors such as the relative abundance and surface distribution of Tspan12, Fzd4, LRP6 and HSPGs.</p><disp-quote content-type="editor-comment"><p>Areas that would benefit from further experiments, or a discussion, include:</p><p>- The authors test a potential composite binding site of Fzd4/Tspan12 heterodimers for norrin using nanodiscs that contain on average about 1 molecule Fzd4 and 1 molecule Tspan12. The Fzd4/Tspan12 heterodimer is co-inserted into the nanodiscs supported by split-GFP tags on Fzd4 and Tspan12. The authors find no major increase in affinity, although they find changes to the Hill slope, reflecting better binding of norrin at low norrin concentrations. In 293F cells overexpressing Fzd4 and Tspan12 (which may result in a different stoichiometry) they find more pronounced effects of norrin binding to Fzd4/Tspan12. This raises the possibility that the formation of a composite binding requires Fzd4/Tspan12 complexes of higher order, for example, 2:2 Fzd4/Tspan12 complexes, where the composite binding site may involve residues of each Fzd4 and Tspan12 molecule in the complex. This could be tested in nanodiscs in which Fzd4 and Tspan12 are inserted at higher concentrations or using Fzd4 and Tspan12 that contain additional tags for oligomerization.</p></disp-quote><p>It is quite possible that Tspan12 and Fzd4 cluster into complexes with a stoichiometry greater than 1:1 in cells (this is supported by e.g., BRET experiments in (Ke et al., 2013)), and we mention in the discussion that that receptor clustering may be an additional mechanism by which Tspan12 exerts its function (page 10, paragraph 4). We would be quite interested to know the stoichiometry of Fzd4 and Tspan12 complexes in cells at endogenous expression levels, both in the presence and absence of Norrin, and to biochemically characterize these putative larger complexes in the future. We have amended the discussion to mention the caveat that our reconstitution experiments do not test higher-stoichiometry Fzd4/Tspan12 complexes (page 10, last paragraph).</p><disp-quote content-type="editor-comment"><p>- While Tspan12 LEL does not bind to Fzd4, the successful reconstitution of GFP from Tspan12 and Fzd4 tagged with split GFP components provides evidence for Fzd4/Tspan12 complex formation. As a negative control, e.g., Fzd5, or Tspan11 with split GFP tags (Fzd5/Tspan12 or Fzd4/Tspan11) would clarify if FZD4/Tspan12 heterodimers are an artefact of the split GFP system.</p></disp-quote><p>The split-GFP system allows us to co-purify receptors that do not normally co-localize (for example, as we have shown with Fzd4 and LRP6 in the absence of ligand (Bruguera et al., 2022)) so we do not mean to claim that it provides evidence for Fzd4/Tspan12 complex formation. In fact, we were unable to co-purify co-expressed Fzd4 and Tspan12 unless they were tethered with the split GFP system, and separately-purified Fzd4 and Tspan12 did not incorporate into nanodiscs together unless they were tethered by split GFP. Based on these experiments, we expect that the purported Fzd4-Tspan12 interaction that others have found by co-IP or co-localization is easily disrupted by detergent, may require a specific lipid, and/or may not be direct.</p><p>To clarify this point, we have noted in the results section that without the split GFP tags, Tspan12 and Fzd4 did not co-purify or co-reconstitute into nanodiscs, and that co-reconstitution was enabled by the split GFP system (page 6, first full paragraph).</p><disp-quote content-type="editor-comment"><p>- Fzd4/Tspan12 heterodimers stabilized by split GFP may be locked into an unfavorable orientation that does not allow for the formation of a composite binding site of FZD4 and Tspan12, this is another caveat for the interpretation that Fzd4/Tspan12 do not form a composite binding site. This is not discussed.</p></disp-quote><p>While the split GFP does enforce a Fzd4/Tspan12 dimer, the split GFP is removed by protease cleavage during the final step of the purification process, after the dimer is contained in a nanodisc. This should allow Fzd4 and Tspan12 to freely adopt any pose and to diffuse within the confines of the nanodisc lipid bilayer. However, it has been shown that the phospholipid bilayer in small nanodiscs is not as fluid as the physiological plasma membrane, and although we used the slightly larger belt protein (MSP1E3D1, 13 nm diameter nanodiscs), perhaps the receptors are indeed locked in some unfavorable state for this reason. Additionally, the nanodiscs are planar, so if the formation of a composite binding site requires membrane curvature, this would not be recapitulated in our system. We have cited these caveats in the discussion section (page 10, last paragraph).</p><disp-quote content-type="editor-comment"><p>- Mutations that affect the affinity of norrin/fzd4 are not used to further test if Fzd4 and Tspan12 form a composite binding site. Norrin R41E or Fzd4 M105V were previously reported to reduce norrin/frizzled4 interactions and signaling, and both interaction and signaling were restored by Tspan12 (Lai et al. 2017). Whether a Fzd4/Tspan12 heterodimer has increased affinity for Norrin R41E was not tested. Similarly, affinity of FZD4 M105V vs a Fzd4 M105V/Tspan12 heterodimer were not tested.</p></disp-quote><p>Since the high affinity of Norrin for both Fzd4 and Tspan12 may have obscured any enhancement of Norrin affinity for Fzd4/Tspan12 compared to either receptor alone, we did consider weakening Fzd-Norrin affinity to sensitize this experiment, inspired by the experiments you mention in (Lai et al., 2017). However, we suspected that the slight increase in Norrin affinity for the Fzd4/Tspan12 dimer compared to Fzd4 alone was driven mainly by increased avidity that enhanced binding of low Norrin concentrations, and this avidity effect would likely confound the interpretation of any experiment monitoring 2:2 complex formation. Additionally, on the basis that soluble Fzd4 extracellular domain and Tspan12 bind Norrin with negative cooperativity (Figures 3D and 3F), we concluded that this composite binding site was unlikely.</p><disp-quote content-type="editor-comment"><p>- An important conclusion of the study is that Tspan12 or Lrp6 binding to Norrin is mutually exclusive. This could be corroborated by an experiment in which LRP5/6 is inserted into nanodiscs for BLI binding tests with Norrin, or Tspan12 LEL, or a combination of both. Soluble LRP6 may remove norrin from equilibrium binding/unbinding to Tspan12, therefore presenting LRP6 in a non-soluble form may yield different results.</p></disp-quote><p>We agree that testing this conclusion in an orthogonal experiment would be a valuable addition to this study. We have now performed a similar experiment to the one you described, but with Norrin immobilized on biosensors, and with LRP6 in detergent competing with Tspan12 LEL for Norrin binding (Figure S12, discussed on page 8, first full paragraph). The results of this experiment show that biosensor-immobilized Norrin will bind LRP6, and that soluble Tspan12 inhibits LRP6 binding in a concentration-dependent manner. The LRP6 construct we use (residues 20-1439) includes the transmembrane domain but has a truncated C terminus, since LRP6 constructs containing the full C terminus tend to aggregate during purification. We chose to immobilize Norrin to make the experiment as interpretable as possible, since immobilizing LRP6 and competing Norrin off with the LEL could result in an increase in signal (from the LEL binding the second available Norrin protomer) as well as a decrease (from Norrin being competed off of the immobilized LRP6). We conducted the experiment in detergent (DDM) instead of nanodiscs to be able to test higher concentrations of LRP6.</p><disp-quote content-type="editor-comment"><p>- The authors use LRP6 instead of LRP5 for their experiments. Tspan12 is less effective in increasing the Norrin/Fzd4/Lrp6 signaling amplitude compared to Norrin/Fzd4/Lrp5 signaling, and human genetic evidence (FEVR) implicates LRP5, not LRP6, in Norrin/Frizzled4 signaling. The authors find that Norrin binding to LRP6 and Tspan12 is mutually exclusive, however this may not be the case for Lrp5.</p></disp-quote><p>This is an important point which we have now addressed in the text (page 8, end of first full paragraph). LRP5 is indeed the receptor implicated in FEVR and expressed in the relevant tissues for Tspan12/Norrin signaling. Unfortunately, LRP5 expresses poorly and we are unable to purify sufficient quantities to perform these experiments. However, LRP5 and LRP6 both transduce Tspan12-enhanced Norrin signaling in TOPFLASH assays (as you mention and as shown by (Zhou and Nathans, 2014)), bind Norrin, and are highly similar (they share 71% sequence identity overall and 73% sequence identity in the extracellular domain), so we expect their Norrin-binding sites to be conserved.</p><disp-quote content-type="editor-comment"><p>- The biochemical data are largely not correlated with functional data. The authors suggest that the Norrin R115L FEVR mutation could be due to reduced norrin binding to tspan12, but do not test if Tspan12-mediated enhancement of the norrin signaling amplitude is reduced by the R115L mutation. Similarly, the impressive restoration of binding by charge reversal mutations in site 3 is not corroborated in signaling assays.</p></disp-quote><p>We agree that testing the impact of Norrin mutations in cell-based signaling assays would be an informative way to further test our model. However, the Norrin mutants we tested generated poor TopFlash signals in all conditions tested. This may be due to general protein instability, weakened affinity for LRP, or weaker interactions with HSPGs. Whatever the cause, the low signal made it challenging to conclusively say whether the Norrin mutations affected Tspan12mediated signaling enhancement.</p><p>When expressed for purification, Tspan12 mutants generally expressed poorly compared to WT Tspan12, so we were concerned that differences in protein stability or trafficking would lead to lower cell-surface levels of mutant Tspan12 relative to WT in TopFlash signaling assays, which would confound interpretation of mutant Tspan’s ability to enhance Norrin signaling.</p><p>Because of these challenges, follow-up experiments to investigate the signaling capabilities of Norrin and Tspan12 mutants were not informative and we have not included them in the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Brugeuera et al present an impressive series of biochemical experiments that address the question of how Tspan12 acts to promote signaling by Norrin, a highly divergent TGF-beta family member that serves as a ligand for Fzd4 and Lrp5/6 to promote canonical Wnt signaling during CNS (and especially retinal) vascular development. The present study is distinguished from those of the past 15 years by its quantitative precision and its high-quality analyses of concentration dependencies, its use of well-characterized nano-disc-incorporated membrane proteins and various soluble binding partners, and its use of structure prediction (by AlphaFold) to guide experiments. The authors start by measuring the binding affinity of Norrin to Tspan12 in nanodiscs (~10 nM), and they then model this interaction with AlphaFold and test the predicted interface with various charge and size swap mutations. The test suggests that the prediction is approximately correct, but in one region (site 1) the experimental data do not support the model. [As noted by the authors, a failure of swap mutations to support a docking model is open to various interpretations. As AlphFold docking predictions come increasingly into common use, the compendium of mutational tests and their interpretations will become an important object of study.] Next, the authors show that Tspan12 and Fzd4 can simultaneously bind Norrin, with modest negative cooperativity, and that together they enhance Norrin capture by cells expressing both Tspan12 and Fzd4 compared to Fzd4 alone, an effect that is most pronounced at low Norrin concentration. Similarly, at low Norrin concentration (~1 nM), signaling is substantially enhanced by Tspan12. By contrast, the authors show that LRP6 competes with Tspan12 for Norrin binding, implying a hand-off of Norrin from a Tspan12+Fzd4+Norrin complex to a LRP5/6+Fzd4+Norrin complex. Thanks to the authors' careful dose-response analyses, they observed that Norrin-induced signaling and Tspan12 enhancement of signaling both have bell-shaped dose-response curves, with strong inhibition at higher levels of Norrin or Tspan12. The implication is that the signaling system has been built for optimal detection of low concentrations of Norrin (most likely the situation in vivo), and that excess Tspan12 can titrate Norrin at the expense of LRP5/6 binding (i.e., reduction in the formation of the LRP5/6+Fzd4+Norrin signaling complex). In the view of this reviewer, the present work represents a foundational advance in understanding Norrin signaling and the role of Tspan12. It will also serve as an important point of comparison for thinking about signaling complexes in other ligand-receptor systems.</p><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>- In Figure 5F high concentrations of transfected Tspan12 plasmid inhibit signaling, which the authors interpret to support the model that Tspan12/Norrin binding prevents Norrin/LRP6/FZD4 complex formation. Alternatively, the cells do not tolerate the expression of the tetraspanin at high levels, for example, due to misfolding and aggregate formation. To distinguish these possibilities: Do high levels of Tspan12 overexpression also inhibit signaling induced by Wnt3a and appropriate Frizzled receptors, even though Tspan12 has no influence on Wnt/LRP6 binding?</p></disp-quote><p>We thank the reviewer for suggesting this important control experiment. We have added the Wnt-simulated TOPFLASH values to the figure in 5F for all conditions. In repeating this experiment, we noticed that high levels of transfected Tspan12 may decrease cell viability and therefore have adjusted the range of transfected Tspan12 in the new Figure 5F (discussed on page 8, second full paragraph). Under this new protocol, both Norrin- and Wnt-stimulated signaling were inhibited by the highest amount of transfected Tspan12. However, Norrinstimulated signaling is inhibited by lower amounts of transfected Tspan12 than Wnt-stimulated signaling, and to a greater extent, supporting our proposed model that Tspan12 competes with LRP for Norrin binding.</p><disp-quote content-type="editor-comment"><p>- Is Tspan12 with c-terminal rho-tag (the form incorporated into nanodiscs) also used for functional luciferase assays, or was untagged Tspan12 used for the luciferase assays in Fig 4D and 5F? Does the c-terminal tag interfere with Tspan12-mediated enhancement of Norrin signaling?</p></disp-quote><p>For the luciferase assays included in this manuscript, wildtype, full-length, untagged Tspan12 is used. We have clarified this in our methods section. When we tested the wildtype vs Cterminally rho1D4-tagged version of Tspan12 in TOPFLASH assays, we saw that the enhancement of Norrin signaling by Tspan12-1D4 was weaker than enhancement by untagged Tspan12. This is consistent with the finding reported in Cell Reports (Lai et al., 2017) that a chimeric Tspan12 receptor with its C-terminus replaced with that of Tspan11 was still capable of enhancing Norrin signaling, though to a lesser extent than WT Tspan12. The deficiency of signaling by our rho1D4-tagged Tspan12 could be due to a difference in receptor expression level or trafficking, but in the absence of a reliable antibody against Tspan12, we were unable to assess the expression levels or localization of the untagged Tspan12 to compare it to the rho1D4-tagged version. (For binding experiments, we reasoned that the C-terminal tag should not affect Tspan12’s ability to bind Norrin extracellularly, especially as we found that purified fulllength Tspan12 and Tspan12∆C (residues 1-252) bound Norrin equally well; we have added this comparison to table S1.)</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>Minor comments.</p><p>Based on the Fzd4-Dvl binding experiment, the authors might state explicitly the possibility that Tspan12's relevance is entirely accounted for by extracellular ligand capture.</p></disp-quote><p>We have stated this possibility explicitly in the discussion section (page 9, last paragraph).</p><disp-quote content-type="editor-comment"><p>Page 4, 3rd paragraph. I suggest &quot;To experimentally test this structural prediction...&quot; rather than &quot;validate&quot;.</p></disp-quote><p>Thank you for this suggestion; we have replaced this wording.</p><disp-quote content-type="editor-comment"><p>This next item is optional, but I hope that the authors will consider it. This manuscript provides an opportunity for the authors to be more expansive in their thinking, and to put their work into the larger context of ligand+receptor+accessory protein interactions. The authors describe the Wnt7a/7b-Gpr124-RECK system and the role of HSPs in Norrin and Wnt signaling, but perhaps they can also comment on non-Wnt ligand-receptor systems where accessory proteins are found. They might add a figure (or supplemental figure) with a schematic showing the roles of HSP and Gpr124-RECK, and some non-Wnt ligand-receptor systems. This would help to make the present work more widely influential.</p></disp-quote><p>Thank you for this suggestion. We have added a figure (Figure 6, discussed on page 10, paragraphs 2 and 3) and expanded our discussion to include other co-receptor systems. We have specifically focused on co-receptors that both capture ligands and interact with their primary receptor(s), thus delivering ligands to their receptors, as we have proposed for Tspan12. Within Wnt signaling, other co-receptor systems with this mechanism are RECK/Gpr124 (for Wnt7a/b) and Glypican-3. We found it interesting that this mechanism is also shared by several growth factor pathways with cystine knot ligands (like Norrin), so we have illustrated and mentioned three of these examples.</p></body></sub-article></article>